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Abstract 
DOT1 is the histone 3 lysine 79 methyltransferase with both unique structure and 
substrate specificity. It plays critical role in telomere silencing maintenance, transcription 
regulation, DNA repair, and cell cycle regulation. DOT1L in mammals is required for 
embryonic development. In the absence of DOT1L, mouse embryos die by E13.5. Severe 
anemia was observed in Dot1L mutant embryos at E10.5. In order to study a potential 
role for DOT1L in embryonic hematopoiesis, colony forming assays were performed 
using both primitive and definitive yolk sac progenitors. We found that DOT1L is 
required for both primitive and definitive hematopoietic development in the mouse. 
Interestingly, there is a specific defect in erythroid lineage development. Using flow 
cytometric analysis, we showed that Dot1L deficiency does not affect the emergence of 
the progenitor population. When Dot1L mutant progenitor cells differentiate into the 
erythroid lineage, they fail to progress normally through the cell cycle and undergo 
increased apoptosis when compared to wild type progenitors. In order to investigate the 
molecular mechanism of DOT1L in hematopoiesis, the expression of genes that are 
critical in hematopoiesis was analyzed in Dot1L mutant progenitors. Although Gata-2 
expression appears to be regulated by DOT1L, the reduction of Gata-2 in yolk sac 
progenitors alone does not lead to an observable hematopoietic defect. Trpc6, which 
plays a role in EPO-mediated calcium influx, was down regulated significantly in Dot1L 
mutant progenitors. Based on our data and previous studies demonstrating a role for 
TRPC proteins in mediating EPO induced calcium influx, I hypothesize that Dot1L 
deficiency results in an abnormal EPO response in hematopoietic progenitor cells. This 
response is characterized by significantly increased calcium influx induced by EPO. This 
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abnormal intracellular calcium levels in turn result in the observed defective 
erythropoiesis. In support of this hypothesis, calcium imaging analysis demonstrated that 
the intracellular calcium level was much higher in Dot1L mutant progenitor cells after 
EPO treatment in comparison with wild type cells. My study explores the cellular and 
biological function of Dot1L and provides more insight into the complex regulation of 
embryonic hematopoiesis. 
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Chapter 1 
Introduction 
            Red blood cells are not only critical for the well-being of adults, but are also 
essential for survival and development of the mammalian embryo beyond the early 
postimplantation stages1. The embryo’s first wave of “primitive” erythrocytes are derived 
from a transient group of committed progenitors from mesoderm-derived cells and are 
first found in the yolk sac as immature precursors2. They then enter the blood stream and 
differentiate in a semisynchronous manner. This first wave of red cell maturation, known 
as “primitive” erythropoiesis, is accompanied by globin gene switching and enucleation. 
Before the end of this first wave of blood development is finished, a second, “definitive” 
wave of erythropoiesis is initiated in the yolk sac3. These definitive erythroid progenitors 
enter the blood stream and seed the fetal liver, where mature erythrocytes are released 
into blood stream. At nearly the same time, hematopoietic stem cells (HSC), which are 
believed to be the source of long-term erythroid potential, emerge in the embryo and also 
seed the liver. Toward the end of gestation, definitive erythropoiesis shifts from the fetal 
liver to its final site, the bone marrow1 (Figure 1.1).  
          Erythropoiesis is a complicated process, with multiple levels of strict regulation at 
various points throughout the process. For instance, at the multipotential progenitor stage, 
the ratio of key transcription factors that are important for lineage determination must be 
controlled precisely, so that the development of each lineage can be ensured4,5. Also, 
erythroid cells must respond properly to certain cytokines, such as EPO, at certain stages 
of development, so they can proliferate and differentiate normally4,6. Thus, expression of 
cytokines, their receptors, as well as the appropriate factors comprising the specific  
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Figure 1.1 The step-wise progression of hematopoietic development in mouse 
embryo. There are two waves of erythroid progenitors emerging in the mouse embryo. 
The first wave consists of primitive erythroid progenitors (EryP-CFC) that emerge in the 
yolk sac at about E7.5. They generate primitive erythroid precursors and start the process 
of enucleation from E12.5. The second wave consists of definitive erythroid progenitors 
(EryD-CFC) and long term hematopoietic stem cells (HSC) from different locations, 
including yolk sac, aorta-gonad-mesonephros  (AGM), placenta, fetal liver (FL), bone 
marrow (BM). Definitive progenitors and HSC use fetal liver and then bone marrow as 
their maturation site.  
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signaling apparatus associated with that factor must be expressed or down-regulated at 
the appropriate times and at appropriate levels. Among factors that contribute to the 
regulation and maintenance of erythropoiesis, the histone 3 lysine 79 methylation has 
emerged as an important player7. The enzyme that catalyzes this modification, Disruptor 
of Telomere silencing (DOT) 1, is expressed in different species and its functions have 
been studied extensively by many groups8-14. Our recent study has shown that DOT1L 
(DOT1 Like, the DOT1 mammalian ortholog) is required for mouse embryonic 
development, particularly playing a role in erythropoiesis7. Recently it has been shown by 
other groups that DOT1L is also required for adult hematopoiesis15. However, the 
molecular mechanism(s) by which DOT1L regulates erythropoiesis is not completely 
understood. In this chapter, I summarize our current understanding about embryonic 
erythropoiesis, DOT1L structure and functions, and recent progress in DOT1L studies.    
           1.1 Embryonic Erythropoiesis 
           Developmentally, erythropoiesis in the mouse begins in the yolk sac/blood islands, 
later at the aorta-gonad mesonephros (AGM) region, the placenta, the fetal liver, and at 
last in the bone marrow toward the end of gestation1,16. In addition to the important 
function of delivering oxygen, red cells in the embryo encounter at least two great 
challenges compared to their adult counterparts. First, the fast-developing embryo at 
postimplantation stages requires functional red cells before the long-term hematopoietic 
stem cell (HSC) and their microenvironmental niches are established. Second, since the 
mammalian embryo grows very fast, embryonic erythropoiesis must generate ever-
increasing numbers of red cells to meet the needs of the growth of the embryo. It has 
been estimated that from embryonic day 12.5 (E12.5) to E16.5, an increase of 70-fold in 
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red cell mass has to be achieved1. Due to its critical function and unique properties, 
embryonic erythropoiesis has been studied for very long time. Nearly 100 years ago, it 
was already recognized that two distinct populations of red cells circulate in the blood 
stream of mouse embryos. The first population, the “primitive” red cells, are extremely 
large, nucleated red cells, which originate from the yolk sac2. Shortly after that, a second, 
“definitive” population, consisting of smaller, enucleated red cells supersedes the 
primitive cells and continues to circulate during the fetal stage and for the entire life of 
the organism3. The paradigm of embryonic erythropoiesis has changed immensely due to 
our increasing knowledge over time. For example, at first the primitive red cells are 
thought to be always nucleated and have the same characteristics with the nucleated 
nonmammalian red cells. Also originally, people believed that definitive erythroid cells 
were derived from a single location. Recent findings have challenged all of these long-
held opinions.  In this section, I will summarize our current understanding of embryonic 
erythropoietic development, as well as some of the important regulatory mechanisms that 
regulate this stage.  
            1.1.1 Development of primitive erythropoiesis 
            During gastrulation, mesoderm cells emerge from primitive streak, which is a 
posterior midline structure of the epiblast. The initial generation of primitive erythrocytes 
relies on the normal development of mesoderm cells. They then migrate to the 
extraembryonic yolk sac, where they differentiate into primitive erythropoietic cells and 
endothelial cells17. It has long been recognized that the yolk sac blood island is the first 
site of hematopoiesis and origin of primitive erythrocytes. The yolk sac is a bilayered 
structure, composed of inner mesoderm and outer visceral endoderm. Blood islands are 
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isolated structures consisting of a cluster of primitive erythroblasts surrounded by these 
two layers18 (Figure 1.2 A). This is the traditional definition of blood islands. Although 
the importance of blood islands as the origin of primitive erythropoiesis has been 
commonly recognized, there is still debate about their morphology. A global view of 
early yolk sac blood and endothelial cell development has been achieved thanks to the 
application of whole mount in situ hybridization and fluorescent immunohistochemistry 
on the whole embryos. It showed that in the yolk sac at E7.75, the blood cells form a 
complete circumferential band in the blood island region. A cross-sectional image of this 
band will give people the impression of isolated island. The band of blood cells is 
subsequently enveloped and then divided by endothelial cells to form many blood-filled 
endothelial channels. When cut cross-sectionally, a single channel would also give people 
the impression of an “isolated” island, which in fact is just an artifact of the sectioning 
and is not a complete view18 (Figure 1.2 B).  
                Primitive erythroid progenitors can be identified in the embryo shortly after 
gastrulation as early as E7.25. Recent studies have shown that the expression of CD41 
(integrin αIIb) is an accurate marker for the earliest erythropoiesis in the yolk sac of 
developing embryo19-21.  The primitive erythroblasts are the descendants of these unique 
CD41-positive progenitors, called primitive erythroid colony-forming cells (EryP-
CFC)22. The colonies derived from these progenitors are distinct from definitive erythroid 
colonies in at least three aspects: first, their maturation time is relatively short (5 days); 
second, their globin gene expression pattern is unique; third, the morphology of the 
colony as well as the individual red cells within the colony is different1 (Figure 1.3).  
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Fiugre 1.2 Different models of yolk sac blood islands. (A). Traditional model of blood 
island development in the mouse embryo between E7.5 and E9.5. Yolk sac blood islands 
form between the single cell layer of endoderm cells (E) and mesothelial cells (open 
arrow). Blood islands develop from undifferentiated mesoderm cells (E7.5, closed arrow) 
that give rise to inner blood cells surrounded by an outer endothelial lining (E9.5, closed 
arrow). (B) A novel model of a “blood island” as a complete band of primitive erythroid 
progenitors (red) and sparse endothelial cells (green) in the blood island region of the 
yolk sac. The primitive capillary plexus (green mesh) separates the blood band from the 
distal embryo proper. Inset box indicates how the blood band would appear in section as 
shown in traditional model. Panel A is from Palis et al, 200123. Panel B is from 
Ferkowicz et al, 200518. 
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Figure 1.3 Morphological comparison between primitive and definitive erythroid 
colonies and erythrocytes. (A-B) Representative pictures of primitive (A) and definitive 
(B) erythroid colonies. (C) Circulating blood cells were isolated both from E9.5 embryos 
and from adult mice, mixed together, cytospun, and stained with Wright-Giemsa. 
Primitive erythrocytes are nucleated and significant larger than the definitive 
erythrocytes. Panel C is from McGrath et al, 20081.  
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            After EryP-CFC are identified in the embryo at about E7.25, they expand very 
fast and reach the peak in numbers at E8.0. After that, their numbers rapidly decrease, 
and they can no longer be found after E9.024. Although the nature of EryP-CFC is 
transient, they are critical for embryo survival and development. The progeny cells of the 
primitive progenitors remain in the circulation of embryo for a prolonged time, together 
with definitive red cells released from fetal liver later on (E12) to perform their function 
of providing sufficient oxygen to the embryo until a relatively late stage of gestation1,24. 
Therefore it is easy to understand that anemia observed before E13 in mouse must be 
attributed to loss or decreased number of primitive red cells. 
            Primitive erythroblasts are released into circulation while they are still immature, 
and it is believed that they undergo maturation in the blood stream1,25. There are two 
important aspects for erythroid maturation: enucleation and hemoglobin accumulation. It 
has been believed for long time that primitive red cells remain nucleated state for all their 
lifetime, a characteristic shared with nucleated red cells of nonmammalian vertebrates. 
However, recent studies have challenged this long-held opinion by showing that primitive 
erythroblasts in the mouse embryo ultimately enucleate, just like their definitive 
counterpart. The time range for mouse primitive erythroblast enucleation is between 
E12.5 and E17.526. Unlike definitive erythroblasts, which mature in erythroblast islands 
of the fetal liver and postnatal bone marrow, primitive erythroblasts are actively 
circulating in the blood stream. Therefore the exact location and mechanism for their 
enucleation is still elusive.  
            A recent study using transgenic mouse models has provided more insight into the 
development of primitive erythroid cells27. In this study, human epsilon-globin gene 
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regulatory elements have been used to drive GFP expression. Only primitive erythroid 
cells express GFP. This is a better and more accurate way to trace primitive erythroid 
cells than by flow cytometry (after staining the cells with lineage markers, such as CD41 
or Tie2). Three developmental niches for primitive progenitor cells were been identified 
in this study: yolk sac, blood stream, and fetal liver. The accumulation of strong GFP-
expressing primitive erythroblasts in the fetal liver was their new finding, since most 
people assumed that fetal liver was the site of maturation for definitive erythroblasts. 
What they found was that erythroblasts accumulate transiently within fetal liver and often 
within erythroblastic islands, in close contact with fetal liver macrophages. Importantly, 
they found that nuclei of primitive erythroblasts labeled by expression of histone-H2B-
EGFP were within fetal liver macrophages in both in vitro culture or in vivo conditions, 
suggesting a possible mechanism whereby primitive erythroblast nuclei were cleared and 
degraded by macrophages at least in fetal liver.   
           The second important aspect of primitive erythroblast maturation is the 
accumulation of hemoglobin. They accumulate increasing amounts of hemoglobin and 
reach their steady-state hemoglobin content (80-100 pg per cell), which is about six times 
the amount of hemoglobin found in definitive erythrocytes. This is in accordance with the 
fact that primitive erythroblasts are about six times larger than definitive erythroblasts1. It 
has been recognized for several decades that primitive erythroblasts contained different 
hemoglobins when compared with their adult counterpart28. The primitive red cells in 
mouse express not only embryonic globins (such as βH1 and εy) but also express low 
levels of adult type globins (β1 and β2). Embryonic hemoglobins in the mouse have 
relatively high affinity to oxygen compared to adult hemoglobins, which potentially 
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facilitates oxygen exchange across the placenta. Interestingly, as primitive erythroblasts 
terminally differentiate, they undergo a process termed “maturational globin switching” 
in which the initially expressed ζ- and βH1-globins are superseded by α1, α2 and ε
y-globins29. These findings indicate that in the primitive erythroid lineage, the α and β 
globin loci are precisely and actively regulated as the cells transition from the progenitor 
stage to a more mature precursor stage. 
                1.1.2 Development of definitive erythropoiesis 
                As I discussed before, since the mammalian embryo grows very fast, 
embryonic erythropoiesis must generate ever-increasing numbers of red cells to meet the 
needs of growth. The number of  red cells generated by primitive erythropoiesis can only 
meet the requirements of the early post-implantation stage. In order to fulfill the 
requirements for cell numbers, a second wave of embryonic erythropoiesis, definitive 
erythropoiesis, begins 24 hours after the primitive erythropoiesis1. This definitive process 
can give rise to larger numbers of erythrocytes, which co-exist with the primitive red 
cells persisting throughout gestation.  
The site(s) of the origin of definitive progenitors has been a subject of 
longstanding debate and intense study. Unlike primitive erythropoiesis, which originates 
from a single site, the yolk sac, definitive erythropoiesis can originate in several possible 
sites, including the yolk sac (YS), aorta-gonad-mesonephros (AGM), and placenta1,17. 
The earliest definitive erythropoiesis potential can be identified in the yolk sac at about 
E8.5 in the mouse. The progenitor cells, however, do not become mature in the yolk sac. 
At this time, the fetal liver serves as the site of the maturation of definitive erythroid 
cells. Definitive progenitors enter the blood steam and seed the fetal liver as soon as it 
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begins to form as an organ at E9.51. The source of the yolk sac progenitors has not been 
clearly resolved. Some groups have suggested that progenitor cells with definitive 
potential from the aorta region may migrate and take up in the yolk sac niche and 
undergo erythropoiesis. While theoretically this may happen, there is currently no strong 
evidence for this. Recently, a study using the Ncx1 KO mouse showed that all primitive 
and definitive hematopoietic progenitor cells before E10 in the mouse embryo are derived 
from the yolk sac17. Ncx1 KO embryonic mice die at E11 because they do not have 
cardiac contractions, but hematopoiesis from E7.0 to E9.5 remains intact. In this study, 
they showed that the total number of primitive and definitive progenitors between Ncx1 
KO and WT is quite similar, but in Ncx1 KO embryos, neither primitive erythroblasts nor 
definitive hematopoietic progenitors could be found in the para-aortic splanchnopleura 
(PSp, a precursor to the AGM) from E8.25 to E9.5. This study indicated that all the 
primitive red cells in the circulation and the definitive progenitors that seed the liver 
before E10 are derived from the yolk sac.  
              Although definitive erythrocytes derived from yolk sac meet the needs of 
embryonic growth temporarily, the continuous generation of blood cells from long-term 
hematopoietic stem cells (HSC) is the ultimate goal of adult hematopoiesis. The first 
long-term HSC, that have the capacity of engrafting adult recipients, have been identified 
in the AGM region at E10.530. In addition to the AGM region, the placenta is also a 
possible origin of HSC and can serve as a site of HSC proliferation31. HSC then migrate 
through the blood stream and seed the fetal liver at E11. The numbers of definitive 
hematopoietic progenitors (BFU-E and CFU-E) increase exponentially for several days in 
the fetal liver and reach a peak at around E14.5-E15.5. Subsequently, the hematopoietic 
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niche shifts gradually from fetal liver to the bone marrow cavity and the fetal liver stops 
functioning as an hematopoietic organ soon after birth1. There is still a disagreement in 
defining definitive erythropoiesis. Some people believe that it should be further divided 
into two waves: one process in which erythrocytes are derived from yolk sac progenitors 
and another in which erythrocytes are derived from long-term HSC. The principal 
differences between the two reside in the cells’ different origins and their slightly distinct 
morphologies1. Other researchers simply group the two populations together and consider 
them both as having the potential to undergo definitive erythropoiesis24. I prefer the latter 
opinion since it is more concise, and use this as a model of embryonic erythropoiesis (see 
Figure 1.1). 
              The origin(s) of primitive and definitive erythroid progenitors has been an 
interesting topic for very long time. Since erythroid and endothelial cells have very close 
spatial and temporal relationship and share some important transcription factors and 
markers, the term “hemangioblast” was coined 100 years ago32. These common 
endothelial and hematopoietic ancestors first appear in the primitive streak in the embryo 
at E7.5. Then the endothelial cells with hematopoietic potential can be identified lining 
the blood islands of yolk sac. The development of in vitro model of embryonic 
hematopoiesis was crucial in the eventual identification of the hemangioblast. The in 
vitro equivalent of the hemangioblast is termed blast colony forming cell (BL-CFC), 
which can generate a blast colony containing both hematopoietic and endothelial cells33. 
The BL-CFC expresses both fetal liver kinase 1 (Flk-1), the vascular endothelial growth 
factor receptor 2, and the mesodermal marker Brachyury. Some researchers have 
challenged the existence of hemangioblasts. For example, Ueno et al. claimed that 
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hematopoietic cells are coming mostly from Flk-1- cells while the endothelial cells are 
generated from Flk-1+ cells34. Soon after that, however, another group refuted their 
results using a simpler and more efficient lineage tracing system, showing that most 
primitive and definitive blood cells are the progeny of Flk-1 expressing hemangioblasts35. 
Another group also demonstrated that hematopoietic cells are generated from 
hemangioblasts through a hemogenic endothelium stage, which is the intermediate 
linking hemangioblast and hematopoietic progenitor36. With accumulated data, more and 
more researchers tend to believe in the existence of hemangioblasts. Table 1 is a 
summary of the important properties of both primitive and definitive erythropoiesis.  
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             1.1.3 Important regulatory mechanisms of embryonic erythropoiesis.  
             Embryonic erythropoiesis in the mouse is a dynamic and complicated process 
that requires the coordinated actions of many molecular mechanisms. When oxygen 
tension in the developing embryo arises, larger numbers of erythrocytes is required to be 
generated to meet the need. This is achieved by increasing red cell proliferation, reducing 
apoptosis, and promoting red cell maturation, through a complex network of interactions 
of transcription factors, responses to certain growth factors, and the activation of 
important signal transduction pathways6. Since the regulation of embryonic 
erythropoiesis is such a broad and complex topic and will be very hard to cover within a 
single discussion, only two important aspects of embryonic erythropoiesis which are 
involved directly in my research will be discussed in the introduction: first, important 
transcription factors and coregulators; second, the important function of erythropoietin 
(EPO).  
           1.1.3.1 Important transcription factors and coregulators in embryonic 
erythropoiesis. 
            When erythroid progenitor cells encounter specific stimuli, such as low oxygen 
tension or cytokines, such as SCF, an erythroid-specific transcription program will be 
created, through which the progenitor cells will fulfill differentiation along different 
lineages37. Erythroid transcription factors were first identified through their binding to the 
promoter regions of some erythroid-specific genes, such as the β-globin gene. Their 
critical functions have been confirmed by both gene knockouts in in vivo systems and 
transcription factor null hematopoietic cell lines, in vitro. In addition, the precise gene 
target networks on a global scale as well as the cis-acting elements of some of the 
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important transcription factors have been identified by chromatin immunoprecipitation 
(ChIP). Through these studies, it has been found that some transcription factors have dual 
functions. They not only activate gene expression required for the generation of the 
erythroid lineage, but they also exert suppression of gene expression of factors important 
for the development of alternative hematopoietic lineages. The important features of 
several key transcription factors in embryonic erythropoiesis and the interactions between 
some of them are discussed below.  
 GATA-1. GATA-1 is the founding member of a small family of zinc finger transcription 
factors that recognize the DNA motif (T/A(GATA)A/G). It was originally isolated as a 
binding protein to the promoter region of the β-globin gene. Subsequent studies showed 
that it is expressed broadly in the erythroid, megakaryocyte, eosinophil, and mast cell 
lineages38. There are three functional domains on the GATA-1 protein. The N-terminal 
domain acts as transcriptional activation domain. Two zinc finger domains are located 
toward the C-terminus of the protein. The zinc finger close to the C-terminus recognizes 
the GATA motifs. The zinc finger close to N-terminus helps stabilize DNA binding and 
has the capacity to interact with other protein factors, such as FOG-1, and erythroid 
Kruppel-like factor (EKLF)39.  
              GATA-1 plays very important role in embryonic erythropoiesis. Loss of GATA-
1 results in embryonic lethality at around E10.5-E11.5 due to severe anemia40. GATA-1 
can promote erythropoiesis by activating transcription of genes that are associated with 
mature red blood cell function and phenotype. GATA-1 null cells (both primitive and 
definitive erythroid progenitors) are not able to differentiate beyond the proerythroblast 
stage and undergo apoptosis41. GATA-1 also performs its function by repressing gene 
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expression. For example, GATA-1 can inhibit the transcription of c-kit and GATA-2, 
whose expression are high at a relatively early stage of embryonic erythropoiesis. The c-
kit and GATA-2 loci contain GATA motifs and are bound by GATA-2 factor at early 
stage of erythroid progenitors, which promotes the transcription of c-kit and GATA-2. 
The expression of GATA-2 and c-kit at this stage is critical for early progenitor survival 
and proliferation. During relatively late stages, GATA-1 expression predominates and 
replaces GATA-2 at the same sites to inhibit GATA-2 and c-kit transcription. By doing 
this, it can help cells in the erythroid lineage undergo maturation4. 
FOG-1 stands for Friend of GATA. As the name implies, it is a very close interacting 
partner of GATA-1, identified through a yeast two-hybrid screen. It is a large protein 
factor containing nine zinc fingers42. FOG-1 is expressed in erythroid cells as well as 
megakaryocytic cells. Its expression pattern is identical to that of GATA-1 and the 
phenotype of the FOG-1 knockout is quite similar to that of the GATA-1 knockout. Both 
result in embryonic lethality at nearly the same stage due to anemia43. The close 
relationship between FOG-1 and GATA-1 is further highlighted by an experiment in 
which the interaction of these two proteins was disrupted by a point mutation. By doing 
this, the experiment showed strong evidence that GATA-1/FOG-1 interaction was 
essential for erythroid differentiation. This study also showed that this protein interaction 
promoted erythroid differentiation by activation and repression of GATA-1 target 
genes44. Despite all these findings, the molecular mechanisms underlying FOG-1 
dependent transcriptional activation and repression are poorly understood. One possibility 
is that FOG-1 facilitates GATA-1 chromatin occupancy at certain loci. Another 
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possibility is that FOG-1 helps facilitate GATA-1-mediated DNA looping, which 
juxtapose the distal enhancer elements to the promoter region, as seen in β-globin locus4.  
GATA-2 is another important member of the GATA family of zinc finger transcription 
factors. It is expressed in hematopoietic stem cells and progenitor cells, endothelial cells, 
and some other tissues, including the central nervous system, placenta, fetal liver and 
heart. GATA-2 knockout experiments in mice showed that no GATA-2 knockout 
embryos survived beyond E11.5. At E10.5, most of the GATA-2 knockout embryos 
(more than 60%) were dead due to anemia, as demonstrated by pale embryos and nearly 
empty yolk sac vessels45,46. In the in vivo and in vitro differentiation analyses using 
GATA-2 null embryonic stem cells, GATA-2 was shown to be required for survival and 
proliferation of immature erythroid progenitors47. Overexpression of GATA-2, induced 
proliferation of progenitors and inhibited progenitor cell maturation48. 
               Despite the unique expression patterns and developmental functions of GATA-1 
and GATA-2, there is considerable interplay between these two factors. As we discussed 
before, GATA-1 can inhibit GATA-2 function and decrease the expression levels of 
GATA-2 target genes at a relatively late stage. This is the so-called “GATA switch” in 
which GATA-2 is displaced from its binding sites by rising GATA-1 levels, facilitated by 
FOG-15. This is a very important process in that it demonstrates the dynamics of 
transcriptional regulation during embryonic erythropoiesis, through which different 
transcription programs are created to meet specific developmental requirements. 
In addition to having opposing effects, recent studies have also showed that 
GATA-2 and GATA-1 can work cooperatively and successively to exert repressive 
effects on gene expression (such as PU.1) during hematopoietic development49. 
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PU.1. PU.1 is encoded by the sfpi1 gene located on chromosome 2 in the mouse. The Ets 
domain on the PU.1 protein corresponds to the DNA binding domain, and can recognize 
the GGAA motif. This Ets domain is also responsible for protein-protein interactions 
between PU.1 and other factors, such as GATA-1 and Runx1. A C-terminal acidic 
domain and a glutamine-rich domain encode the transcriptional activation activities37,50.  
PU.1 expression is mostly restricted to the hematopoietic system and its 
expression pattern is highly dynamic, characterized by sharp on/off transitions50. For 
example, PU.1 is actively expressed in early hematopoietic cells, including hematopoietic 
stem cells and multipotential progenitor cells. However, once the progenitor cells become 
committed to the erythroid/megakaryotic lineage, a marked decrease in PU.1 expression 
is observed. In erythroid cells, PU.1 expression is low in immature stages 
(CD71+TER119- population), and becomes completely undetectable in more mature cells 
(CD71+TER119+)50,51. It is believed that during embryonic erythropoiesis, a low level of 
PU.1 is required for promoting the self-renewal potential of erythroid progenitors. PU.1 
knockout embryos die in late gestation and are devoid of fetal liver B lymphocytes, 
granulocytes, and macrophages. PU.1 null progenitor cells showed reduced proliferative 
capacity52.  
Although so far, most data support an important role of PU.1 in the 
development of the myeloid lineage, it is also very important to note that interactions 
between PU.1 and GATA family proteins are critical for the development of 
erythropoiesis. People have found that PU.1, GATA-1 and GATA-2 are all expressed in 
multipotential progenitor cells49. During lineage commitment, the activation of specific 
transcription factors and the interactions between different factors will direct the 
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progenitor cells down a particular differentiation pathway. The interaction between these 
two protein families has been demonstrated by several studies in the past ten years. First, 
GATA proteins inhibit the functions of PU.1. GATA-2 and GATA-1 can work together 
and successively to inhibit PU.1 function in the erythroid lineage49. Specifically, PU.1 
needs to perform its full transcriptional activity by binding to its cofactor c-Jun. However 
GATA proteins can interact with a small region no larger than 12 amino acids within the 
PU.1 C-terminal Ets domain. As a result of this binding, GATA proteins could destroy 
the interaction between PU.1 and c-Jun53. It has also been showed that GATA-1 inhibits 
PU.1 not only by physical protein interaction, but also by repressing PU.1 transcription49. 
On the other hand, PU.1 can inhibit GATA-1 function and erythroid differentiation by 
blocking GATA-1 DNA binding54. Interestingly, PU.1 inhibits GATA-1 function not 
through the same C-terminal Ets domain. In contrast, it has been found that the N-
terminal 70 amino acids of PU.1 are essential to repress GATA-1 function by blocking its 
DNA binding. PU.1 can also inhibit GATA-2 expression51. Therefore, we can see that the 
relative amount of GATA proteins and PU.1 and their interactions are critical in 
determining lineage commitment of progenitor cells. A negative cross-talk between PU.1 
and GATA proteins has been established as a model to describe their functions and 
interactions. In stem cells or multipotential progenitor cells, GATA-2 predominates to 
help maintain the expression of PU.1 at an intermediate level. This is consistent with the 
concept “lineage priming” whereby both myeloid genes (PU.1) and erythroid genes 
(GATA-2) are expressed at moderate, but detectible levels in multipotential progenitors, 
to help maintain their plasticity. Upon erythroid/megakaryocytic differentiation, GATA-1 
is highly expressed and displaces GATA-2 through the so called “GATA switch”. 
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GATA-1 is thought to be a stronger repressor of PU.1 and it can repress PU.1 at both the 
transcriptional and protein levels. Therefore PU.1 function is shut down completely. At 
the same time, GATA-1 helps ensure terminal erythrocyte maturation. Alternatively, 
during myeloid differentiation, both GATA-1 and GATA-2 are repressed, which allows 
for higher-level PU.1 expression and interaction of PU.1 with c-Jun, and consequently 
the increased expression of downstream target genes53.  
EKLF. The Erythroid Kruppel-like Factor (EKLF) is crucial for erythropoiesis and for 
β-globin gene expression5. It is an erythroid-specific, zinc finger transcription factor and 
binds to CACC box motifs which can be found in the promoter region of β-globin and 
many other erythroid genes55. The EKLF gene knockout mouse shows embryonic 
lethality at about E14-15 due to severe anemia56,57. When the β-globin gene locus was 
analyzed in the gene knockout embryos, it showed that the promoter region and the locus 
control region (LCR) assumed a “closed” chromatin structure, resulting in failed β-
globin activation58. This indicates that EKLF has an important role in organizing an 
active chromatin domain in β-globin as well as other erythroid gene loci. Initial studies 
suggested that EKLF solely plays its role in definitive erythropoiesis. More recent studies 
demonstrated that it is also involved in primitive erythropoiesis59.	
CBP.  The major function of CBP and its paralog p300 is to acetylate histones as well as 
other non-histone proteins. They are very important in mouse embryonic development. 
CBP knockout resulted in embryonic lethality due to developmental retardation and 
defects in multiple systems, including deficient primitive and definitive erythropoiesis5. 
In the hematopoietic system, it plays an essential role in maintaining the self-renewal 
ability of hematopoietic stem cells and is required for differentiation60. CBP can also 
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expand its capacity by working with other protein factors. For instance, CBP can interact 
and acetylate GATA-1 and increase the DNA binding ability of GATA-1. Another 
example is that EKLFs ability to bind a chromatin remodeling complex is greatly 
enhanced by EKLF acetylation by CBP/p3005. 	
SCL. SCL is a member of the basic helix-loop-helix family of transcription factors and 
binds a DNA motif (CANNTG) called the E-box. SCL performs its function by forming a 
protein complex, called a “pentameric complex” with other factors, such as LMO2 and 
GATA-1. The targets of this complex involve many erythroid genes and the regulatory 
elements of key transcription factors61. SCL knockout embryos die before E9.5 and show 
a complete absence of primitive erythrocytes and myeloid progenitors in yolk sac. SCL 
null ES cells fail to contribute to any hematopoietic lineage either in vivo or in vitro62,63. 
Recent studies have shown that SCL is not required for generation of Flk+ 
hemangioblasts, but is critical for generation of endothelial and hematopoietic lineages 
from these cells. After generation of the endothelial lineage and hemogenic endothelium 
(from which the hematopoietic lineage is derived), SCL is no longer critical, as deletion 
of SCL in Tie2+, VE-cadherin+ cells does not affect hematopoiesis64.	
TRAP220. TRAP220 or Med1 is the mediator subunit that constitutes a key component 
of mediator originally found to associate with nuclear hormone receptors5. Deletion of 
TRAP220 results in lethality at E11.5 due to anemia, although the hematopoietic 
progenitor cell number remains normal. TRAP220 deficient progenitor cells have a defect 
specifically in erythroid lineage formation (shown by defective BFU-E and CFU-E), but 
not in the formation of the myeloid lineage65. Recent studies using TRAP220 conditional 
knockout mice, has confirmed this specific block in erythroid development, but not in 
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myeloid or lymphoid development in vivo. Importantly, β-globin gene expression is 
abrogated in TRAP220 knockout embryos66. Therefore, TRAP220 is critical in erythroid 
development and β-globin gene activation.    
            1.1.3.2 The important function of EPO during erythropoiesis. 
            Regulation of erythropoiesis is a complex process involving the function of a 
number of external factors. Many factors such as cytokines contribute to this process. For 
example, interleukin-3 has been shown to increase the number of BFU-E, while Stem 
Cell Factor increases the number of both BFU-E and CFU-E6. Receptors for Insulin are 
expressed at later stages of erythroid differentiation and their ligands show anti-apoptotic 
effects on differentiating erythroid cells67. Transforming Growth Factor α and β have 
also been shown to regulate erythrocyte numbers68. In addition, some nuclear hormones 
are also closely involved in erythropoiesis. For instance, T3 has been shown to regulate 
proliferation/differentiation of erythropoiesis either positively or negatively at different 
developmental stages, suggesting that it may exert its function in a time-specific 
manner69.  
            Among all of these factors, EPO is considered the primary regulator of 
erythropoiesis. Since the identification of EPO, the life quality of patients with anemia 
due to chronic kidney disease has been dramatically improved and EPO has become the 
world’s leading biopharmaceutical. The importance of the EPO response is demonstrated 
by EPO or EPO receptor (EPOR) mutant animals. Mice with mutated EPO/EPOR die due 
to anemia during embryogenesis at E12.5-13.5, a stage of massive erythroid expansion70.  
              EPO signaling pathway is initiated by EPO’s binding to its specific, high-affinity 
receptors. EPOR was first identified in 1989 and it belongs to the type-I superfamily of 
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single-transmembrane cytokine receptors. It is expressed in the erythroid progenitor cells 
derived from bone marrow or yolk sac. It is also found in several non-hematopoietic 
tissue including myocytes, cortical neurons, and breast and ovarian epithelia71. In the 
erythroid lineage, it is first expressed at the BFU-E stage, and all the way through the 
orthrochromatic erythroblast stage6.  
              When EPO binds EPOR, the receptors will form homo-dimers and undergo a 
conformational change. The cytoplasmic domain of EPO receptor contains two 
membrane motifs called Box-1 and Box-2, to which the tyrosine kinase JAK2 binds. The 
conformational change of EPOR during dimerization induces the reciprocal trans-
phosphorylation of JAK2, therefore activating JAK2. Phosphorylated JAK2 can then 
phosphorylate the eight tyrosine residues on the EPO receptor’s cytoplasmic domain, 
forming a docking site for SH2 containing molecules associated with the EPO signal 
transduction cascade6. From this point, a number of signaling pathways can be initiated:  
1) JAK2, in collaboration of a second kinase, Lyn, will activate STAT protein 
family members. Tyrosine phosphorylation followed by dimerization has been shown to 
activate ten members of the STAT family, which can act as transcription factors. Among 
these members, EPO receptors specifically activate STAT5a and STAT5b isoforms. One 
of the critical target genes of STAT5 is the anti-apoptotic molecule Bcl-XL. Anemia was 
observed in animals with conditional knockout of Bcl-XL in the erythroid lineage. 
Therefore the activation of this pathway by EPO is critical for enhancing survival and 
proliferation of erythroid progenitors72.                       
2) The EPO response also activates PI3 kinase, which in turn stimulates the 
PKB/Akt pathway. PKB/Akt pathway has been shown to mediate anti-apoptotic and 
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proliferative signals. For example, studies using an apoptosis-resistent erythroid cell line 
showed that activation of PI3 kinase is required to prevent apoptosis. A mouse model 
with mutated p85 α subunit of PI3 kinase showed markedly reduced BFU-E and CFU-E 
populations, which resulted in an erythropoiesis defect. Some downstream substrates of 
PKB/Akt have been proposed. An important example is forkhead box O3A (Foxo3a), a 
transcription factor that can be inhibited by phosphorylation. The targets of Foxo3a 
include BTG1 and p27Kip1. Both these factors have putative anti-proliferation and anti-
differentiation functions73. 
3) Another pathway activated by EPO is PLCγ signaling. Activation of PLC
γ will generate the second messenger inositol-1,4,5-trisphosphate (IP3). Studies have 
shown that a conformational change of IP3 receptor upon IP3 binding will facilitate its 
association with the transient receptor potential channel (TRPC) proteins, which are 
voltage-independent calcium channels74. TRPC proteins will then mediate calcium influx 
into erythroid progenitors, which is required for normal erythropoiesis75,76.  
Another interesting finding is that during erythropoiesis, EPO does not work 
alone. A study showed that there was cooperation between c-kit and the EPO receptor, 
linking these two pathways77. SCF and EPO pathways can work at different stages of 
erythropoiesis to improve cell survival. In the immature erythroid cells, SCF signaling is 
dominant and induces Bcl-2, EPOR and Stat5 expression. Bcl-2 is the major player of 
promoting survival. While erythroid cells undergo terminal differentiation, GATA-1 
expression results in down-regulation of c-kit and Bcl-2 and up-regulation of EPOR. The 
increased EPO signaling pathway results in up-regulation of Bcl-XL, which replaces Bcl-2 
and performs an anti-apoptotic function. 
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The EPO induced signaling pathways are not limited to the above mentioned. 
Due to limited space and relevance to my study, only these three are discussed. In the 
following paragraphs, I am going to discuss the PLCγ and calcium pathways in more 
detail, because of their strong relevance to our research.  
Calcium is a universal signaling molecule that can regulate a variety of aspects 
of cellular function. New life begins with a surge of calcium at fertilization. Thereafter, 
this versatile signaling molecule is used again and again in many processes during 
development and in the adult, including embryonic pattern formation, cell differentiation, 
cell proliferation, and transcription factor activation78. Dysregulation of calcium signaling 
has been implicated in cancer development79. In addition, calcium is one of the key 
elements in apoptotic signaling pathways. Several calcium-mediated apoptosis 
mechanisms have been explored. Mitochondria are usually close to the calcium channels 
of the endoplasmic reticulum (ER). Calcium released from ER will be absorbed by 
mitochondria, leading to mitochondrial swelling and apoptosis. The calpains, calcium 
activated cysteine proteases, when induced by some stimuli, can cleave and activate a 
number of molecules that have important functions in apoptosis, including caspase-12 
and Bax. Calmodulin (CaM) is the major sensor of intracellular calcium and is also 
involved in many apoptotic pathways78.  
Importantly, much research has shown that regulation of intracellular calcium 
by EPO plays a critical role in erythroid progenitor cell differentiation, proliferation and 
survival75,76. For example, treatment of ethylene glycol tetraacetic acid (EGTA), a 
nonspecific calcium chelator, can inhibit EPO-induced murine red cell colony growth, 
while treatment of an ionophore could enhance colony growth by increasing calcium 
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influx80. In a murine erythroleukemia cell line, it was demonstrated that an increase in 
calcium influx is required for the commitment of differentiation76,81. In CFU assays using 
human hematopoietic progenitors, increases of calcium concentration in response to EPO 
were observed during different stages of differentiation, suggesting that a calcium signal 
is required throughout erythropoiesis75. In our study, the Dot1L mutant yolk sac 
hematopoietic progenitors, which exhibit an erythropoietic defect, also show abnormal 
calcium influx when treated with EPO. Moreover, the ability of EPO to activate calcium 
influx and influence cell proliferation and survival has also been demonstrated in 
nonerythroid cells, such as myoblasts and brain tissue82. All of these studies suggest that 
EPO, as a growth factor, has a very broad role in maintaining proliferation and preventing 
apoptosis in different cell types, and highlight the importance of understanding the 
calcium influx mechanism by EPO.  
It has been established that EPO causes a calcium influx through a transient 
receptor potential (TRP) protein superfamily, first identified in Drosophila83. Based on 
sequences from Drosophila TRP, a large number of mammalian isoforms were cloned 
and have been divided into six subfamilies. One of the subfamilies, TRPC, has been 
investigated in depth and was confirmed to be major players in EPO-mediated calcium 
influx83. In the mouse, it has been shown that among the six members of the family, 
TRPC1 to TRPC6, only TRPC2 and a certain amount of TRPC6 mRNA and protein are 
expressed in hematopoietic cell lines84. In this study, researchers used a CHO cell model 
system and showed that EPO is able modulate calcium influx through TRPC2. EPO, 
external calcium, TRPC2 and EPOR are all required for a calcium rise. The function of 
TRPC6 and its relationship to TRPC2 were investigated subsequently by the same group. 
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In this study, they first confirmed that EPO could regulate calcium influx in primary 
hematopoietic cells harvested from the spleens of phenylhydrazine-treated mice and 
showed that both TRPC2 and TRPC6 were expressed in these primary cells by RT-PCR, 
Western blotting, and confocal microscopy. They used transfected CHO cells as the 
model system, in which the TRPC composition can be controlled. They found that EPO 
stimulated a significant increase in calcium in cells transfected with TRPC2 isoforms, 
which was consistent with their previous study. But EPO did not induce a calcium influx 
in cells transfected with TRPC6. In cells transfected with both TRPC2 and TRPC6, these 
two protein factors were associated and calcium influx was inhibited. This indicates that 
the stoichiometry of expression of TRPC2 and TRPC6 is an important determinant by 
which hematopoietic cells regulate calcium influx in response to EPO stimulation85. A 
cell poised for response to EPO has a certain ratio of TRPC2 to TRPC6, and expression 
of these proteins is required for the normal response. Any change in the expression of 
either of these two factors will affect this ratio and result in altered calcium influx when 
the cells are exposed to EPO. The magnitude of the calcium response to EPO is thus 
regulated. This regulation has potential to affect the cellular response to EPO, with one 
ratio resulting in nominal responses, leading to normal erythropoietic development. Too 
little or too much of either of these channels can lead to too little or too great a calcium 
response, leading to overexpansion of an erythroid response or potential hematopoietic 
defects due to enhanced apoptosis of progenitor cells. In human cells, TRPC2 is a 
pseudogene, and EPO regulates calcium influx through TRPC3.   
How does the EPO signaling pathway results in TRPC family activation and 
calcium influx? It turns out that the bridge between the two events is phospholipase Cγ 
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(PLCγ). Several studies have shown that EPO stimulation of its receptor induces 
tyrosine phosphorylation and activation of PLCγ74,84. PLCγ activation produces IP3, 
which activates the IP3 receptor (IP3R). IP3R then is able to interact with TRPC2. The 
association of IP3R and TRPC2 results in a conformational change of TRPC2 and 
opening of the calcium channel.  
            1.2 Histone H3 lysine 79 (H3K79) methylation by DOT1 
methyltransferase  
            In eukaryotic cells, DNA is packaged within the nucleus along with histones and 
other nuclear proteins to form the nucleosome, the fundamental repeating unit of 
chromatin. The nucleosome is composed of a histone core octamer, made up of two each 
of H2A, H2B, H3, and H4 histones and a string of 146 basepairs of DNA wrapped 
around this histone core86. The histone proteins have a distinct globular domain with 
unstructured N- and C- terminal tails. The histone proteins (especially the tails) can be 
post-translationally modified in a variety of ways, including acetylation, phosphorylation, 
ubiquitination, and methylation. Among these modifications, acetylation and 
phosphorylation are reversible and seem to be associated with inducible regulation of 
genes, while histone methylation is more stable and seems to be transmitted in a heritable 
manner87. These modifications can influence chromatin structure, facilitate interactions 
between nucleosomes, and can potentially regulate transcription. Moreover, these 
modifications that occur at different sites of histones can create huge amount of diversity 
in terms of histone/nucleosome modifications, due to multiple combinations of different 
types of these enzymatic modifications on individual histone proteins87. Different 
proteins can bind specifically to the various forms of histone tails as a result of different 
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combinations of histone modifications. The binding of different protein factors results in 
distinct chromatin-dependent functions, such as gene activation or repression, or 
heterochromatin formation. This phenomenon was proposed as the “histone code 
hypothesis”. According to this hypothesis, different histone modifications can be 
translated to biological signals and act as signaling platforms to elicit downstream nuclear 
responses88.  
Most of the histone modifications occur on histone tails because they are 
relatively unstructured and exposed to a variety of nuclear factors including enzymes that 
catalyze different states of modifications and other protein factors that interact 
specifically with different types of histone modification. Histone lysine methylation, 
which is one of the covalent histone modifications, exists in mono, di, and tri states87. 
One way that these methyl marks contribute to transcriptional regulation is to serve as a 
platform for the recruitment of effector proteins. The well-studied lysine methylation 
residues include K4, K9, K27, K36, and K79 of histone H3, and K20 of histone H4. In 
general, methylation at H3K9, H3K27, and H4K20 correlates with transcriptional 
repression, while methylation at H3K4, H3K36, and H3K79 correlates with 
transcriptional activation88. In addition to its role in transcriptional regulation, 
methylation has also been linked to X inactivation, cell fate determination, terminal 
differentiation, and the spatiotemporal patterning of Hox genes. Moreover, aberrant 
histone methylation has also been linked to various human cancers87. Histone lysine 
methylation is catalyzed by one family of histone lysine methyltransferases (HLMT).  
              1.2.1 The characteristics and protein structure of DOT1. 
Most histone lysine methyltransferases contain a conserved SET (suppressor of 
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variegation, enhancer of zeste, and trithorax) domain, which is required for enzymatic 
activity and is believed to be a signature motif for this class of enzymes. In contrast, 
DOT1, the H3K79 methyltransferase, is quite different from most of HLMT family 
members. In the first place, unlike other histone lysine methyltransferases, DOT1 family 
members do not have a SET domain. Instead, their catalytic domain contains conserved 
sequence motifs characteristic of class I methyltransferases such as DNA 
methyltransferases (DNMTs) and the protein arginine methyltransferase PRMT189,90. In a 
previous study, the crystal structure of human homolog of DOT1, hDOT1L, was 
determined at 2.5Å resolution. First, the researchers found that the N-terminal α-helical 
domain of hDOT1L contains the HLMTase catalytic activity. Although the full-length 
hDOT1L contains 1537 amino acids, only the N-terminal ~360 amino acid share 
significant sequence homology with other species, such as yeast DOT1 and Drosophila 
homolog. Within this region, they found that amino acids 1-416 contain 
methyltransferase activity in an in vitro assay. Second, they found hDOT1L contains a S-
adenosyl-L-Methionine or SAM binding motif, instead of a SET signature domain of 
other HLMTases.  SAM binding motifs are characteristic of protein lysine and arginine 
methyltransferases. During the methyltransferase reaction, SAM donates a methyl group 
to a lysine or arginine amino acid. In proximity of SAM binding motif, they also found a 
potential lysine binding channel, through which lysine 79 of H3 could access the active 
site and is brought close SAM group. Finally, a disordered C-terminal region was shown 
to be important. Within this region, amino acids 391-416, which are enriched with 
positively charged residues, are crucial for HLMT activity. In the following gel mobility 
shift assays, this region showed important nucleosome binding function and it was 
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required for normal enzymatic activity90. Due to the structural similarity between DOT1 
and arginine methyltransferases, it has been speculated that whether DOT1 possesses the 
ability of arginine methylation. However, this function has failed to be proven even 
though people put in extensive efforts using the most advanced technologies. 
Secondly, the substrate, H3K79 is located at the loop 1 region between α1 and 
α2 helixes within the globular domain of histone H3 and exposed on the nucleosome 
surface and do not interact with DNA or other histones, as revealed by an X-ray crystal 
structure analysis8,90,91 (Figure 1.4 A). This region is also close to the interface between 
H3/H4 tetramer and H2A/H2B dimer86. Therefore H3K79 is positioned in a place where 
it can influence the access to the interface, suggesting the possibility that H3K79 
methylation may regulate the interaction of protein factors to chromatin, such as silencing 
proteins. For example, Sir proteins (silent information regulator) as well as other 
silencing proteins and chromatin remodeling complexes, which are important for folding 
of nucleosomes into silent chromatin, may be regulated by H3K79 methylation. 
           When the enzymatic activity of DOT1 was studied, it showed that DOT1 
preferentially methylated H3K79 in the context of nucleosomes rather than core histones 
or recombinant H310. This observation suggested that DOT1 not only recognizes H3K79, 
but may also recognize other conformational features of the nucleosomes. As previously 
discussed, H3K79 is located at the loop 1 region of histone H3 within the globular 
domain and exposed on the nucleosome surface. It also lies in close proximity to the 
interface between the H3/H4 tetramer and H2A and H2B dimer. Based on the observation 
that DOT1 preferentially works on nucleosomes and specific position of H3K79, it has  
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Figure 1.4 The location of H3K79 on the nucleosome. (A) The structure of the yeast 
nucleosome core particle, viewed down the superhelical axis (left) and side view (right). 
H3K79 is shown in red space filling, while the histone protein main chains are 
represented as yellow ribbons. Gray lines indicate DNA. (B) The crystal structure of the 
human nucleosome (PDB code 3AFA) is shown on the left. Histone H2A is shown in 
light green, H4 is shown in sand, H2B is shown in hot pink, and H3 is shown in blue. A 
close-up view of the nucleosome surface is on the right, with the location of H2B-K120 
shown as yellow spheres and H3K79 shown as green spheres. Note that H2B-K120 and 
H3K79 are located in proximity on the same exposed surface of the nucleosome. Panel A 
is from van Leeuwen et at, 200210. Panel B is from Nguyen et at, 201192. 
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been suggested that DOT1 function is regulated by trans-histone cross-talk. X-ray crystal 
structure study showed that H3K79 and H2B-K123 are adjacent on the same exposed 
nucleosome surface (Figure 1.4 B). H2B-K123 can be mono-ubiquitinated by the 
ubiquitin-conjugating E2 enzyme Rad6 and ubiquitin E3 ligase Bre1. It would be 
interesting to determine whether there is a cross-talk between the modifications on 
H3K79 and H2B-K123. Importantly, the deletion of Rad6 not only abolished H2B 
ubiquitination, but also destroyed H3K4 and H3K79 methylation. Mutation of H2B-K123 
also resulted in lack of H3K4 and H3K79 methylation, indicating that H2B ubiquitination 
is required for H3K4 or H3K79 methylation. In contrast, the deletion of DOT1 does not 
influence H2B-K123 ubiquitination, suggesting that H2B ubiquitination is the 
prerequisite for DOT1 function, and works upstream of the trans-histone pathway93. Then 
how does H2B-K123 mediate H3K79 methylation? So far, there are three possible 
mechanisms and they are not mutually exclusive. 1). H2B-K123ub can interact with 
DOT1 indirectly through some other protein(s). In support of this, studies showed that 
H2Bub can recruit protein factors Rpt4 and Rpt6 to chromatin to facilitate H3K79 
methylation. 2). H2B-K123ub can interact with DOT1 directly. It has been shown that N-
terminal of DOT1 contains a lysine-rich region, through which DOT1 can interact 
directly with ubiquitin. Deletion of this region resulted in failure of nucleosome binding 
and diminished di- and trimethylation of H3K79. 3). Ubiquitination of H2B results in 
chromatin structure changes to facilitate DOT1 function. Evidence is that ubiquitination 
of H2B can disrupt chromatin compaction and interchromatin fiber interactions to 
increase substrate accessibility92. Current literature supports the notion that all of these 
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nonexclusive mechanisms work together to facilitate H3K79 methylation mediated by 
H2B ubiquitination.  
            Although H3K79 methylation process has been extensively studied, the 
mechanism of demethylation of this mark is still largely unknown. So far, at least one 
histone demethylase exists for each known histone lysine residues subject to methylation, 
except for H3K79. But there is already some evidence suggesting that this elusive 
H3K79-specific demethylase does exist. For example, in both yeast and human cells, the 
H3K79 di-methylation level fluctuates with cell cycle89,94. Also, H3K79 di-methylation 
level reduced during early embryonic development in mice, suggesting the existence of a 
demethylase in mature oocytes95,96. It should not take very long before the identity of the 
enzymes(s) is unveiled.  
            1.2.2 Important functions of DOT1 
            As we discussed before, DOT1 is a histone lysine methyltransferase that is 
responsible for H3K79 methylation. H3K79 methylation is conserved between different 
species, from yeast to human. There are three types of methylation on this site: mono-, di-
, and tri- methylation. So far, the DOT1 is thought to be the sole enzyme responsible for 
these modifications in all species. Mutation of Dot1 in different model system results in 
specific ablation of H3K79 methylation, while modifications on other sites of histone are 
not affected in general7,89,92. Therefore DOT1’s function in cells is thought to be non-
redundant. Through modifications on H3K79, tremendous cellular and physiological 
function can be regulated by DOT1.  
           DOT1 was initially identified in Saccharomyces cerevisie as a disruptor of 
telomeric silencing97. In subsequent studies, both over expression and inactivation of 
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DOT1 or mutations at H3K79 lead to loss of telomeric silencing10. A possible 
explanation came from the nuclear redistribution of Sir2 and Sir3 proteins in Dot1 mutant 
yeast. Telomeric silencing is critically dependent on the Sir proteins, which are recruited 
to telomeres by DNA binding protein Rap1 and other associated protein factors10. 
Chromatin immunoprecipitation analyses provided evidence that Sir2 and Sir3 
association with telomeric DNA is diminished in the Dot1 mutant, and this effect is even 
more significant when H3K79 is mutated. However at the same time, in the subtelomeric 
region, Sir2 and Sir3 binding was increased in Dot1 mutant10. It seems that Dot1 is not 
required for Sir proteins binding, but precludes their binding. Based on these 
observations, a model was generated in which H3K79 methylation limits Sir protein 
binding and silencing to discrete loci, while it precludes their binding elsewhere in the 
genome. According to this model, Dot1 mutation results in elimination of H3K79 
methylation, leading to promiscuous binding of Sir proteins in genome and titrating the 
limited pool of Sir proteins away from telomeres. Over expression of DOT1 results in 
hypermethylation of H3K79 and leaves little unmodified histone H3 in the nucleus, 
which also impairs telomere-Sir protein association and a general loss of silencing 
throughout the genome. Under both conditions, telomeric silencing is disrupted98-100. On 
the other hand, another member of Sir protein family, Sir3 has been shown to inhibit 
H3K79 methylation by competing with DOT1 for binding to the same basic patch 
(R17H18R19) of the histone H4 tail, which is required for DOT1 function
101,102. Thus, the 
balance of Sir protein amount and level of H3K79 methylation is very important for 
heterochromatin formation and telomeric silencing maintenance.  
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Besides its important function in telomere silencing, genome-wide analysis 
also connects H3K79 methylation with active transcription. Some early studies in yeast 
showed that about 10% of the genome is enriched with Sir proteins and hypomethylated 
at H3K79. These regions correspond to low levels of transcription. In contrast, 90% of 
the yeast genome is highly methylated at H3K79 and these regions are actively 
transcribed10,103. This correlation has also been observed by other groups, showing that 
H3K79 methylation can be found at active V(D)J recombination sites using mammalian 
cell lines104. Despite these initial works, the following studies with the help of high-
throughput technology to map specific chromatin modifications on a genome-wide scale 
have generated inconsistent results. Some research supported this positive correlation 
between H3K79 methylation and transcription. For instance, in Drosophila, chromatin 
immunoprecipitation coupled with gene expression microarray (ChIP-chip) confirmed the 
correlation by showing that H3K4 and H3K79 methylation are associated with active 
gene transcription105. In contrast, some other research showed different results. For 
example, in two studies, ChIP-chip assays were also carried out in yeast and human T 
cells. But they did not find a significant correlation between H3K79 methylation and 
transcriptional activity106,107. Several important caveats to these data have been described, 
and these may alter the interpretation of the results of these studies. First, the authors 
relied exclusively on micrococcal nuclease digestion of chromatin and it was shown that 
sometimes this method does not work as efficiently as sonication. Second, they 
performed ChIP in the absence of sodium dodecyl sulfate (SDS). SDS results in partial 
denaturation and exposure of H3K79 methylation, which is required for detection within 
formaldehyde-cross-linked chromatin92. After that, several studies came out in support of 
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this positive correlation. In 2008, Steger et al. observed the ubiquitous nature of DOT1L 
recruitment and H3K79 methylation at actively transcribed sites. A strong similarity 
between the patterning of H3K79 methylation and that of H3K4 methylation in 
mammalian chromatin was identified, which suggests that parallel pathways may exist to 
specify gene activity or antagonizing gene silencing. Also they found that H3K79 mono-
methylation is enriched in intergenic regions and is usually associated with regulatory 
proteins, suggesting H3K79 mono-methylation may demarcate gene-regulatory elements 
in the genome13. Findings reported in this report from our laboratory are consistent with 
this positive correlation. In the G1E mouse cell line, we demonstrated H3K79 mono-, di- 
and tri-methylation are all enriched in the important regulatory regions, such as the 
promoter and enhancers in the Gata-2 locus, which is actively transcribed. In contrast, on 
the silenced pu.1 locus, there is only H3K79 mono-methylation observed at the promoter 
and upstream regulatory elements. No H3K79 di and tri-methylation enrichment are 
observed in these regions7 (see Figure 4.3). Collectively, analyses from yeast, mouse, 
Drosophila, and human genomes indicate that H3K79 methylation is indeed associated 
with active transcription. 
An interesting phenomenon is that although H3K79 methylation is a universal 
histone modification that can be found throughout the genome, the knockout of Dot1 only 
results in transcriptional changes in a subset of genes, but not all of them. For instance, in 
Steger’s study in 2008, they found that although there is strong correlation between 
H3K79 di- and tri-methylation and transcriptional activity, many active genes can still be 
transcribed at normal levels in the absence of H3K79 methylation in their transcribed 
region. Another study using embryonic stem (ES) cells investigated the consequence of 
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Dot1L deficiency in the transcriptome. They found that under both standard ES cell 
culture condition and after 3-days of retinoic acid (RA)-induced differentiation, Dot1L 
deficiency resulted in expression changes in a group of genes in the whole genome, most 
of which have known functions in the cell cycle, cellular proliferation and 
differentiation108. In our research, which is focused on Dot1L function in embryonic 
hematopoiesis, we analyzed expression change of genes important in hematopoiesis in 
Dot1L KO progenitor cells using RT-PCR. We found that only some critical transcription 
factors and a voltage-independent calcium channel change their transcription level upon 
Dot1L KO, while most other genes, including hemoglobin genes and cytokine receptors, 
are not affected by Dot1L loss7.  
DOT1 plays important role in the DNA damage response. The first evidence 
for this came from a study showing that H3K79 methylation can interact with the tudor 
domain of human 53BP1 protein and recruit it to DNA double strand breaks (DSBs). 
Dot1L knock down or mutation of tudor domain of 53BP1 both inhibited 53BP1 
recruitment to DSBs. This is a conserved mechanism since this phenomenon can be 
observed from yeast to mammalian cells109. Later on, studies showed that DOT1 is also 
required for the DNA damage checkpoint response. When yeast cells are treated with 
ionizing radiation (IR), they usually undergo a G1 checkpoint delay, a surveillance 
mechanism allowing time for DNA repair. Dot1 mutant yeast cells are defective in G1 
and intra-S phase checkpoint11. Importantly, mutations that may affect DOT1 function 
also results in the same defect. This includes Rad-Bre1 pathway required for H2B 
ubiquitination, mutation of H2B lysine 123, or mutation of H3K79. The molecular 
mechanism is that loss of DOT1 prevents the binding of the yeast 53BP1 ortholog Rad9 
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to DSBs, which in turn prevents the recruitment and activation of Chk2 homolog Rad53 
kinase, a key step in DSB repair pathway110-112. DOT1 was also found to be required for 
other types of UV-induced DNA damage besides DSB and meiotic checkpoint control in 
yeast110,113. However, the knowledge about DOT1L’s function in DNA damage 
checkpoint control in mammalian is quite limited.  
DOT1’s function is not only investigated in cell lines and lower eukaryotes, 
Dot1L deficient mouse lines have been established by several groups to study its 
biological function in the whole organism. In 2008, Jones, et al. generated a mouse line in 
which exon 5 and 6 of Dot1L gene encoding 108 amino acids that form several conserved 
motifs in the catalytic domain were deleted. They showed for the first time that Dot1L is 
essential for mouse embryonic development and Dot1L deficiency results in embryonic 
lethality. At E8.5, no distinguishable defect was observed between Dot1L KO and WT 
control. By E9.5 Dot1L KO embryos are smaller than littermates, have severe cardiac 
dilation and stunted tails upon gross observation under a dissecting microscope. By 
E10.5, the percentage of viable Dot1L KO is much lower than the expected Mendelian 
ratio, and no Dot1L KO embryos survive beyond E10.5. They also derived ES cells from 
this Dot1L KO mouse line and showed that Dot1L deficiency results in ES cell growth 
defects, telomere elongation, aneuploidy, and loss of heterochromatin marks at telomeres 
and centromeres12. In order to further study Dot1L’s function in fetal heart development, 
a cardiac-specific Dot1L KO mouse model was generated. When Dot1L was only 
deficient in cardiac system, increased mortality rate with chamber dilation, increased 
cardiomyocyte cell death, systolic dysfunction, and conduction abnormalities were 
observed. Importantly, similar defects are also obvious in patients with dilated 
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cardiomyopathy. Mechanistic studies showed that the transcription of dystrophin is 
regulated by DOT1L-mediated H3K79 methylation. The stability of dystrophin-
glycoprotein complex is important for cardiomyocyte viability and dystrophin may be a 
major target mediating DOT1L function in cardiomyocytes114. This study not only 
revealed the mechanism by which Dot1L performs its function in cardiac system, but also 
raised the possibility of diagnosis and treatment of certain human heart diseases.  
The studies in our laboratory were based on a mouse line in which a gene trap 
was used to abrogate Dot1L activity (Figure 1.5). Our results were consistent with the 
previously described study that DOT1L function is essential for embryogenesis, with 
embryonic lethality occurring at mid-gestation in Dot1L deficient mice. Importantly, we 
found that a defect in early erythropoiesis is attributed to embryonic lethality. We also 
reported that in hematopoietic progenitor cells of these embryos, two genes critical for 
early hematopoietic fate decision, Gata-2 and pu.1, were differentially affected by the 
loss of Dot1L function7. Consistent with our results about Dot1L function in 
hematopoiesis, recently another group using a conditional knockout model showed that 
Dot1L is also required for murine postnatal hematopoiesis. By doing flowcytometry and 
transplantation experiments, they showed that deletion of Dot1L leads to pancytopenia 
and failure of hematopoietic homeostasis, and Dot1L deficient cells are incapable of 
reconstituting recipient bone marrow115. This research is a good extension of our Dot1L 
study and their results are meaningful. But the researchers did not provide any 
mechanistic explanation about Dot1L’s function in postnatal hematopoiesis.  
In addition to its role in normal hematopoiesis, DOT1L is also strongly 
associated with leukemias resulting from translocation of MLL gene, in which MLL is  
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Figure 1.5 Illustration of gene trap. (A) Typical gene trapping vector, showing the 
splice acceptor (SA), the internal ribosomal entry site (IRES), the β-geo gene (fusion of 
the the β-galactosidase gene and the neomycin-resistance gene), and the polyadenylation 
site (PA). (B) Conventional genomic DNA, showing exons and introns. (C) Resultant 
mRNA after gene trapping insertion between Exon1 and Exon2. On transcription to form 
mRNA, the SA allows the vector to be spliced to exon1. Transcription is terminated 
before exon2 because of the existence of a poly-A site on the vector. The presence of the 
IRES ensures the translation of the β-geo marker. 
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fused in frame with dozens of translocation partners. The misregulation of DOT1L is 
achieved because many MLL translocation partners, including AF9, ENL, AF4, AF10, 
EAP, SEC, etc., can interact with DOT1L, therefore DOT1L is recruited to MLL fusion 
protein target genes116. For example, in MLL-AF10 transformed cells, both MLL-AF10 
fusion protein and H3K79 di-methylation were enriched at Hoxa9, which is important in 
leukemogenesis and is a target of MLL-AF10. DOT1L enzymatic activity is required for 
Hoxa9 gene overexpression116. DOT1L has also been shown to be required for both 
initiation and maintenance of MLL-AF9 mediated leukemogenesis in vivo and in vitro. In 
this study, the researchers indicated that the recruitment of DOT1L to MLL-AF9 target 
genes, enrichment of H3K79 methylation on these locus, and up-regulation of important 
oncogenes, such as Hoxa and Meis1 constitute the molecular basis of MLL-AF9 induced 
leukemogenesis117,118. Collectively, current data support a general mechanism by which 
DOT1L contribute to leukemogenesis process: interaction between DOT1L and MLL 
fusion partners results in abnormal recruitment of DOT1L to the gene targets of MLL 
fusion proteins, some of which are critical oncogenes. The subsequent aberrant H3K79 
methylation enrichment leads to constitutive over expression of these genes, which in 
turn facilitates leukemic transformation. Based on this assumption, it may be possible to 
treat certain types of leukemia if DOT1L enzymatic activity or DOT1L interaction with 
MLL fusion proteins is specifically inhibited119. But due to DOT1L’s role in normal 
hematopoiesis, the possible side effect should be taken into account before this method is 
applied to leukemia patients. 
In summary, DOT1 is a histone lysine methyltransferase with both unique 
structure and substrate specificity. It plays critical role in telomere silencing maintenance 
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and is capable of regulating transcription at both heterochromatin and euchromatin. 
Generally, H3K79 is enriched at actively transcribed gene loci. In addition to 
transcription, DOT1 plays an important role in DNA damage checkpoint response. 
Moreover, DOT1L in mammals is required for embryogenesis, cardiac development and 
hematopoiesis. It also plays a pivotal role in MLL-induced leukemogenesis. However, it 
turns out that activity of DOT1 and its associated H3K79 methylation is extremely 
complicated. Besides its function in cardiovascular and hematopoietic systems, DOT1’s 
function in other aspects needs to be elucidated. A thorough characterization of DOT1 
function will not only help us understand its essential role in normal biological process, 
but will also provide us a potential avenue to the treatment of certain human diseases. In 
chapter 2, materials and experimental methods used in my study are described. In chapter 
3, the erythropoietic defects in Dot1L mutant yolk sac cells are discussed. In chapter 4, 
two hypotheses are discussed. My first hypothesis is that DOT1L is required for 
maintaining the normal level of Gata-2 and pu.1 in the hematopoietic progenitor cells. 
When Dot1L is mutated, it will directly result in transcription pattern change of Gata-2 
and pu.1, which in turn causes specific erythroid development defect. My second 
hypothesis is that Dot1L deficiency results in down regulation of Trpc6. The change of 
stoichiometry of TRPC6 and TRPC2 in turn results in abnormal calcium influx in 
response to EPO during erythropoiesis, which leads to specific erythropoietic defect. 
Experimental results are described and discussed. Chapter 5 is used for summarization of 
previous results and discussion for future directions.  
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Chapter 2  
Materials and Methods 
2.1 Standard solutions and reagents:  
mEPO  
1X105 units/ml mEPO (PeproTech) in water with 0.1%BSA, stored at -20°C. 
SCF 
10 ug/ml SCF (R&D) in sterile PBS containing 0.1%BSA, stored at -20°C. 
Puromycin:  
1mg/ml in water, stored at -20°C. 
Amphicilin (stock solution): 
100mg/ml in 50% water and 50% ethanol.  
Roswell Park Memorial Institute medium (RPMI) complete medium (for K562 cells 
growth):  
RPMI 1640 with 1% sodium pyruvate, 1% non-essential amino acid, 1% L-glutamine, 
10% FBS, and 1% penicillin/streptomycin, filter sterilized, stored at 4°C. 
Isocove’s Modified Dulbecco’s Medium (IMDM) complete medium (for G1E cells 
growth):  
IMDM with 0.01% monothioglycerol, 1% penicillin/streptomycin, 15% FBS, mEPO 
2U/ml, SCF 100ng/ml, filter sterilized, stored at 4°C. 
Methylcellulose medium for primitive erythropoiesis: 
Methylcellulose (R&D Systems) with 10% plasma-derived serum (Antech Inc), 5% 
protein free hybridoma medium (Gibco-BRL), and cytokines SCF (100ng/ml) and mEPO 
(2U/ml), stored at -20°C.  
Methylcellulose medium for definitive hematopoiesis:  
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MethCult GF3434 methylcellulose medium with recombinant cytokines for mouse cells 
(StemCell Technologies), stored at -20°C. 
Methylcellulose medium for definitive erythropoiesis: 
MethCult SF3334 methylcellulose medium with recombinant cytokines for mouse 
erythroid progenitor cells (StemCell Technologies), stored at -20°C. 
Yolk sac digestion solution: 
PBS containing 20% FBS and 0.1% collagenase (StemCell Technologies), stored at 4°C.  
Benzidine staining stock solution: 
100 mg Benzidine (Sigma-Aldrich) suspended in 50ml 0.5M acetic acid, stored at 4°C. 
To make working solution: add 20 ul 30% hydrogen peroxide (H2O2) into 1ml of the 
Benzidine stock solution, then mix with 4 ml Dulbecco’s Modified Eagle Medium 
(DMEM) medium. Freshly made before experiment. 
Hemin stock solution (for K562 cell differentiation): 
4mM hemin, 0.02mM NaOH, 0.05mM Tris.HCl pH7.8, filter sterilized and stored at  
-20°C. Working concentration is 50uM. 
TBS buffer 10X: 
24.23 g Trizma HCl, 80.06 g NaCl, suspended in 800 ml ultra pure water. Adjust pH to 
7.6 with HCl and top up to 1 liter.  
TBST: 
100 ml TBS 10X+900 ml ultra pure water+1ml Tween20 
Lysis buffer for Western Blot: 
  150 mM sodium chloride 
  1.0% NP-40 (Triton X-100 can be substituted for NP-40) 
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  50 mM Tris, pH 8.0 
Loading buffer for Western Blot: 
NuPAGE LDS sample buffer 4X (Life Technologies) 
Running buffer for Western Blot: 
1X Tris-glycine buffer containing 25 mM Tris base, 190 mM gycine, 0.1% SDS, pH 8.3. 
Transfer buffer for Western Blot: 
The same as running buffer with the addition of methanol to a final concentration of 20%.  
SDS lysis buffer: 
1% SDS, 10mM EDTA, 50mM Tris.HCl pH8.0, stored at room temperature. 
ChIP dilution buffer: 
0.01%SDS, 1.1%Triton X-100, 1.2mM EDTA, 167mM NaCl, 16.7mM Tris.HCl pH8.0, 
stored at room temperature.  
Low salt immune complex wash buffer: 
0.1%SDS, 1%Triton X-100, 2mM EDTA, 150mM NaCl, 20mM Tris.HCl pH8.0, stored 
at room temperature. 
High salt immune complex wash buffer: 
0.1%SDS, 1%Triton X-100, 2mM EDTA, 500mM NaCl, 20mM Tris.HCl pH8.0, stored 
at room temperature. 
1X TE buffer: 
10mM Tris.HCl pH8.0, 1mM EDTA, stored at room temperature. 
LiCl immune complex wash buffer: 
0.25M LiCl, 1% NP-40, 1% deoxycholate, 1mM EDTA, 10mM Tris.HCl pH8.0, stored at 
room temperature.  
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          2.2 Animal Husbandry 
           2.2.1 Generation of Dot1L mutant mice and breeding scheme  
          A mouse ES cell line (Sequence Tag, RRR032) that contains a gene-trap 
integration within exon 13 of the Dot1L gene and a β-geo selection cassette was 
obtained from Bay Genomics. Dot1L-mutant mice were generated by using the 
recommended protocols of Bay Genomics for blastocyst injection and mouse breeding 
(http://baygenomics.ucsf.edu/protocols/comp1/blastocyst.html). Dot1L heterozygous 
(Dot1L+/-) F1 mice were generated by breeding chimeras with C57B1/6 females (The 
Jackson Laboratory). Stocks of heterozygous mice were maintained by continuous 
backcrossing to C57B1/6 stocks. Generation of Dot1L-/- embryos was achieved by 
crossing male Dot1L+/- and female Dot1L+/-. 
           2.2.2 Genotyping of progeny 
          The genotypes of all offspring were analyzed by PCR on genomic DNA isolated 
from ear punches, tail tips, or embryonic tissue depending on the intended protocols. 
Genomic DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen). The 
presence of the gene trap was tested with the primers (Dot1L Forward 5'- 
TGGACACTTACCCAGCACTTCC-3', Wild Type reverse 5'- 
GAGGGAGATGGCTTTTTGACAGTAG-3', Dot1L KO reverse 5'- 
TTTGAGCACCAGAGGACATCCG-3'). The wild type allele gives rise to a band of 
326-bp band. The Dot1L KO allele containing the gene trap gives rise to a band of 271-
bp band. The heterozygous progenies generate both bands.  
          2.2.3 Animal euthanasia  
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          All mice used in this study were sacrificed by asphyxiation with carbon dioxide 
followed by cervical dislocation to confirm mortality or by direct cervical dislocation 
according to IACUC standard operating procedure (SOP).  
       2.3 DNA manipulations 
        2.3.1 Genomic DNA isolation 
        Genomic DNA was isolated from mouse and embryonic tissues using the DNeasy 
Blood and Tissue Kit (Qiagen). Briefly, tissues from mouse ear or tail tips and embryonic 
tissue were incubated overnight in 180 ul ATL buffer (tissue lysis buffer) and 20 ul 
proteinase K. The following morning the samples were vortexed and 200 ul buffer AL 
and 200 ul absolute ethanol were added to the samples and mixed thoroughly. The entire 
sample was pipetted into DNeasy Mini spin column and centrifuged at 6000 x g for 1 
minute. Next, 200 ul buffer AW1 (wash buffer 1) was added to the column and again 
centrifuged for 1 minute at 6000 x g. Then 500 ul buffer AW2 (wash buffer 2) was added 
and centrifuged at 20,000 x g for 3-5 minutes. The column was placed in a clean 1.5 ml 
Eppendorf tube and appropriate amount of buffer AE (elution buffer) was added directly 
onto the column membrane. The sample was incubated at room temperature for 1 minute 
and then centrifuged for 1 minute at 6000 x g to elute. DNA samples were frozen at -
20°C until use.  
         2.3.2 Polymerase Chain Reaction (PCR) 
         4X primer stock solution was obtained by dissolving PCR primers (Integrated DNA 
Technologies, Inc) in pure water to a concentration of 100 uM (100 p Mole/ul). Primers 
were stored at -20°C. PCR reactions were carried out on 2720 Thermal Cycler (Applied 
Biosystems). PCR products were analyzed in 2% agarose gels.  
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A typical PCR cocktail:  
10X Tsg reaction buffer 2.5 ul 
25 mM magnesium chloride 3 ul 
dNTPs 1 ul  
Tsg DNA polymerase 0.2 ul 
Primer (forward) 0.5 ul 
Primer (reverse) 0.5 ul 
Water 15.3 ul 
Template 2 ul 
Total 25 ul 
Typical conditions for PCR (annealing temperature and cycle number varied): 
95°C 5 minutes 
--------------------------------------- 
94 °C 45 seconds 
61°C 45 seconds             30 cycles 
72 °C 100 seconds 
--------------------------------------- 
72 °C 10 minutes 
4°C hold 
     2.4 RNA manipulations  
      2.4.1 RNA isolation 
      RNA extraction using TRIzol (Invitrogen) was performed following standard 
protocol. Cells to be analyzed were washed with PBS. Then the cells were centrifuged at 
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2300 rpm for 3 minutes at 4°C and discarded the supernatant. 1ml TRIzol per 1X106 was 
added to cell pellet and an 18 gauge syringe was used to disrupt the pellet. The samples 
were incubated at room temperature for 3 minutes. The cellular debris was removed by 
centrifugation at 12,000 g for 15 minutes at 4°C. The supernatant was transferred to 1.5 
ml Eppendorf tubes and equal volume of isopropanol was added to precipitate the RNA. 
The samples were incubated at room temperature for 15 minutes and then centrifuged at 
15,000 g for 15 minutes to pellet the RNA. Supernatant was discarded and the RNA was 
washed in 70% ethanol. Samples were centrifuged at 15,000 g for 15 minutes and 
supernatant was discarded. Finally the RNA pellet was resuspended in appropriate 
amount of water.  
         2.4.2 Reverse Transcriptase (RT)-PCR 
        cDNA was generated using SuperScript VILOTM cDNA Synthesis Kit 
(Invitrogen). For a single reaction, 5X VILOTM Reaction mix 4ul, 10X SuperScript 
Enzyme mix 2ul, RNA (up to 2.5 ug) and water were mixed to total volume of 20ul. The 
sample was incubated at 25°C for 10 minutes and then incubated at 42°C for 60 minutes. 
The reaction was terminated at 85°C for 5 minutes. cDNA samples were stored at -20°C.  
         2.4.3 Real-time PCR for gene expression analysis 
        Sequences of real-time PCR primers were obtained from either Primer Bank 
(http://pga.mgh.harvard.edu/primerbank/) or designed with MacVector software 
(MacVector Inc.). Quantitative real-time PCR was performed and analyzed with the 7500 
real-time PCR system (Applied Biosystems). Fold change was calculated by the ΔΔ/Ct 
method. Gene expression was normalized to GAPDH.  
       2.5 Preparation of single yolk sac cell suspension 
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         Yolk sacs from embryos at ages E8.5 or E10.5 were used in my research. Embryos 
were obtained from timed mating between heterozygous Dot1L-mutant mice. Yolk sacs 
were incubated in 0.1% collagenase (StemCell Technologies Inc) in PBS with 20% FBS 
at 37°C for 30 minutes. The digested yolk sacs were aspirated through 25- and 27-gauge 
needles sequentially and then filtered through a 70-uM nylon strainer (BD Biosciences). 
Genotyping was performed on DNA isolated from corresponding embryo tissues.  
        2.6 Culture of mouse embryonic fibroblasts 
          E10.5 embryos were dissociated by aspiration through a 25-gauge needle. Cells 
were incubated in 12-well plates at 37°C in complete Dulbecco modified Eagle medium 
(DMEM)/10% FBS until confluent. Mouse embryonic fibroblasts (MEF) were then 
incubated in DMEM with 0.1% FBS for 72 hours, restimulated with DMEM with 20% 
FBS for 24 hours, and harvested for analysis.  
        2.7 Extraction of histone from both starved and restimulated MEF 
         MEF were washed twice with ice-cold PBS with 5mM sodium butyrate then 
trypsinized and resuspended (107cells/ml) in Extraction Buffer (TEB: 0.5% Triton X-100, 
2mM phenylmethylsulfonyl fluoride, 0.02% NaN3 in PBS). The MEF/TEB suspensions 
were incubated on ice for 10 minutes and centrifuged at 800g for 10 minutes at 4°C. The 
supernatant was discarded, and the pelleted nuclei were washed in one-half the volume of 
TEB and centrifuged as before. The nuclear pellets were resuspended in 0.2N HCL at a 
density of 4-107/mL at 4°C overnight. The samples were centrifuged (800g), and 
supernatant was analyzed. Protein content was determined by the Bradford assay (Bio-
Rad), and aliquots were stored at -80°C. 
       2.8 Whole-mount immunolabeling for fluorescence 
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         Embryos were dissected at E10.5 in PBS. The uterus and decidua were carefully 
removed and discarded. The yolk sac was separated from the embryo by severing the 
vitelline arteries and the embryo was used for genotyping. The yolk sacs were collected 
in separate wells in 24-well plate and then fixed in 1mL of 3% paraformaldehyde/PBS for 
15 minutes on ice. Yolk sacs were permeabilized in PBS containing 0.2% Triton X-100 
for 30 minutes. Nonspecific binding was blocked by incubation with 3% BSA plus 5% 
donkey serum in PBS for one hour at 20°C. Tissues were then incubated with anti-
platelet endothelial cell adhension molecule 1 (CD31, BD PharMingen) at 4°C overnight, 
then washed 5 times in 0.5 mL blocking solution for one hour each. A fluorescein 
isothiocyanate-coupled donkey anti rat secondary antibody (1:75 dilution in blocking 
solution, 4°C overnight) was used for detection (Jackson ImmunoResearch Laboratories 
Inc). The yolk sacs were then mounted onto glass slides with the use of an anti-
photobleaching medium for immunofluorescence detection. 
        2.9 Analysis of primitive and definitive hematopoiesis by colony 
forming unit assay 
        Primitive erythropoiesis was measured by performing colony-forming unit assay. 
Briefly, E8.5 yolk sacs were dissected and dissociated into single cell suspension. Equal 
number of cells from each yolk sac (3x104) were plated in methylcellulose containing 
10% plasma-derived serum (Antech Inc), 5% protein free hybridoma medium (Gibco-
BRL), and cytokines KL (100 ng/ml) and EPO (2 U/ml). Colonies were identified, 
counted and measured after 5-7 day culture in incubator with 95% humidity, 5% CO2 
and 37°C. In order to analyze definitive hematopoiesis, erythroid burst-forming unit 
(BFU-E) and granulocyte, macrophage colony-forming unit (CFU-GM) assays were 
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performed. E10.5 yolk sacs were dissociated into single cells and 5x104 cells from each 
yolk sac were plated in M3434 methylcellulose medium (StemCell Technologies) in 35-
mm culture dishes. Cell culture was incubated at 37°C, 5% CO2, with 95% humidity for 
10-12 days. In some experiments, cells were plated on medium (M3334) that only 
supports the growth of erythroid lineage (CFU-E and mature BFU-E colonies) and 
cultured for 2-3 days for colony identification and counting.  
          Cultures were viewed with a NIKON ECLIPSE TS100 microscope equipped with 
10X to 20X phase contrast, numerical aperture 1.2 objective lens. Images were taken with 
a LEICA DFC480 camera with the use of Leica Firecam software at room temperature. 
Single-colony area was measured with ImageJ software (National Institutes of Health).  
        2.10 Benzidine staining of erythroid colonies or hemoglobin-containing 
K562 cells 
         A benzidine solution containing 0.6% (wt/vol) benzidine base, 2% (vol/vol) 
hydrogen peroxide, and 12% (vol/vol) acetic acid was used. For observation of primitve 
erythroid colonies derived from E8.5 yolk sacs and BFU-E colonies derived from E10.5 
yolk sacs, benzidine solution was directly applied on the surface of methylcellulose 
medium for 5 minutes. Then the stained colonies were viewed with a NIKON ECLIPSE 
TS100 microscope equipped with 10X to 20X phase contrast objective lens. For K562 
cell observation, cells were washed with PBS and resuspended in the benzidine solution 
for 5 minutes. Then the percentage of benzidine positive K562 cells was determined 
using a light microscope with at least 500 cells counted each time.  
       2.11 Giemsa staining of blood smear of circulating blood from E10.5 
embryos 
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         To analyze the morphology of primitive red blood cells, intact E10.5 embryos were 
dissected out of the yolk sac and each was transferred into a 35mm dish with 3 ml PBS. 
Yolk sacs were opened with tweezers and the embryos were transferred to a fresh dish of 
PBS containing 12.5 ug/ml Heparin. The umbilical vessels were severed near the 
embryo’s body wall. A pipette was used to aspirate and prevent both the clotting at the 
exit site and clotting of blood cells in the medium. Once the embryo stopped bleeding, 
medium was collected and centrifuged. The primitive blood cells were then resuspended 
in 3ul PBS for making blood smears on a microscope slide. The slide was fixed for 60 
seconds in methanol and submerged in 1 ml of Wright Giemsa Stain (Fisher Scientific 
Company) for 1 to 2 minutes. 1.5 ml of pH6.8 Diluted Buffer (made by mixing pH6.8 
Buffer (Fisher Scientific Company) 30 ml with 100 ml of deionized water) was added to 
the stain-covered slide. The slide was gently rocked for 1 minute to mix the stain and 
buffer together. The slide stayed 2 more minutes in the mixture. After that, the slide was 
rinsed with deionized water and allowed to air dry. Slides were viewed using a NIKON 
ECLIPSE 55i microscope with NIKON Plan 40X objective lens. 
       2.12 Cell cycle and apoptotic study 
        Single cell suspensions were made from E10.5 yolk sacs, and were cultured in 3334 
medium (StemCell Technology) at 37°C for 3 days for apoptosis analysis and for cell 
cycle studies. Briefly, methylcellulose medium in each dish was dissolved thoroughly in 
1X PBS 10 ml. The medium was centrifuged at 1500 rpm for 7 minutes. The cells were 
resuspended in 1 ml cold PBS and readied for use. For apoptosis analysis, 1X105 cells 
from each sample were stained with annexin V-phycoerythrin (BD Biosciences) and 
Topro 3 (Molecular Probes), following the instructions of the manufacturer. For cell 
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cycle studies, the cells were stained with propidium iodide. All analyses were performed 
by flow cytometry with the use of the BD FACSCalibur Flow Cytometer (BD 
Biosciences). 
       2.13 K562 cell hemin induction  
        K562 cells (empty vector control and Dot1L KD) were maintained in RPMI 
complete medium (1% sodium pyruvate, 1% non-essential amino acid, 1% L-glutamine, 
10% FBS, and 1% penicillin/streptomycin) containing puromycin 1ug/ml, hemin 50uM at 
concentration of 500X103 cells/ml in a 24-well plate. Cells were cultured at 37°C for 36-
48 hours. Then cells were centrifuged and supernatant was discarded. Cells were washed 
2 times with RPMI complete medium to get rid of exogenous hemin. Finally cells were 
resuspended in 80ul complete medium and ready for benzidine staining analysis.  
        2.14 Dot1L knock down in K562 cells 
         Lentiviral vectors pGIPz and pLKO.1 containing shRNA targeted to hDot1L as well 
as empty control vectors (Open Biosystems) were amplified in LB medium with 
100ug/ml Ampicillin. Minipreps (Qiagen) were performed to extract sufficient amount of 
plasmids for K562 cell transfection. Briefly, pelleted bacterial cells were resuspended in 
250 ul Buffer P1 and transferred to a microcentrifuge tube. 250 ul Buffer P2 was added 
and the tube was inverted 4-6 times to mix well. 350 ul Buffer N3 was added and the tube 
was inverted 4-6 times immediately, but gently. The tube was centrifuged for 10 minutes 
at 13,000 rpm (~17,900xg) in a table-top microcentrifuge. The supernatant in the tube 
was poured or pipetted into the QIAprep spin column. The column was centrifuged for 
30-60 seconds and flow-through was discarded. 0.75 ml Buffer PE was added to wash the 
column and centrifuge for 30-60 seconds. Flow-through was discarded and centrifuge for 
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an additional 1 minute to remove residual wash buffer. Then the QIAprep column was 
placed in clean 1.5 microcentrifuge tube. To elute DNA, 50 ul Buffer EB was added to 
the center of the QIAprep spin column, let it stand for 1 minute, and centrifuge for 1 
minute. DNA concentration was determined by NanoDrop ND 1000 spectrophotometer 
(Thermo Scientific). Transfection of K562 cells with lentiviral vectors was performed per 
the following protocol (for each sample):  
1) resuspend 1X106 cells in 1 ml Opti-MEM® (Invitrogen);	
2) mix 1.6 ug plasmid DNA with 100ul Opti-MEM®; 	
3) mix Lipofectamin (Invitrogen) 4ul and 96ul Opti-MEM®. Stay at room temperature 
for 5 minutes;	
4) mix solutions from step 2) and 3). Stay at room temperature for 20 minutes;	
5) add mixture from step 4) to the 1 ml cells in Opti-MEM® in one well of a 6-well plate. 
After culture cells in 37°C incubator for 5 hours, 1ml RPMI complete medium was 
added; 
6) next day, puromycin was added at concentration of 1ug/ml. 
After one week, the majority of transfected K562 cells were puromycin-resistent. And 
pGIPz vector transfected cells were more than 90% GFP positive. Certain amount of cells 
was used to perform real-time PCR to test Dot1L knock down efficiency.  
         2.15 Lentiviral transduction of G1E cells 
          Lentivirus was produced by transfection of HEK293T cells with shRNA plasmid 
(pGIPz) targeted to mDot1L (Open Biosystems). The day before transfection (day0), 
plate the HEK293T cells at a density of 5.5X106 per 100 mm plate in complete medium 
(DMEM supplemented with 5% heat inactivated FBS, 100units/ml penicillin and 
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100ug/ml streptomycin). On the day of transfection, 37.5ug DNA was diluted into 1ml of 
serum-free medium in a 1.5ml tube. 187.5ul of Arrest-In (Open Biosystems) was diluted 
into 1ml of serum-free medium in a separate 1.5ml tube. The diluted DNA and the 
diluted Attest-In reagent in the two tubes were mixed rapidly to form the transfection 
complexes and incubated for 20 minutes at room temperature. The complete growth 
medium was aspirated from the HEK293T cells. The transfection complexes and an 
additional 3ml of serum free medium (total 5ml) were applied onto the cells. The plate 
was returned to into 37°C incubator with 5% CO2 for 3-6 hours. Then the transfection 
mixture was aspirated and 12ml standard culture medium was applied. The cells were 
returned to 37°C incubator with 5% CO2. After 48-72 hours of incubation, GFP 
expression was examined microscopically, which is an indication of transfection 
efficiency. Virus-containing supernatant was harvested 48-72 hours post-transfection by 
removing medium to a 15ml sterile, capped conical tube. For each transduction, 1X106 
G1E cells were resuspended in 2ml virus-containing medium in one well of a 6-well plate 
supplemented with 15% FBS, 50ng/ml SCF, 2U/ml EPO. Puromycin was added to 
concentration of 1ug/ml after cells were cultured in 37°C incubator for 24 hours. GFP 
positive cells were monitored as an indication of transduction efficiency.  
        2.16 Bone marrow and liver cell extraction from tissue 
         Bone marrow cells (Trpc6 highly expressed) were isolated from mouse femurs. 
Mice were sacrificed using CO2 and cervical dislocation and was saturated with 70% 
alcohol. The skin was cut and removed from the lower part of the body. Remaining 
muscles from the pelvic and femoral bones were cleaned. Each end of the bone was cut 
and a 25g needle and 5ml syringe filled with cold PBS were used to expel bone marrow 
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from both ends of the bone into a 50ml Falcon tube. Then a 27g needle attached to a 5ml 
syringe was used to aspirate and expel the bone marrow cells until the cell aggregates 
were broken up. For liver cell isolation, mouse liver was dissected into cold PBS. The 
whole liver tissue was minced into small pieces. The tissue pieces were ground between 
two pieces of microscope slides in PBS containing protein inhibitor cocktail (Sigma, 
P8340), until no big chunks of tissue were visible. The suspension was passed through a 
70um nylon strainer (BD Biosciences) to obtain single cells. The bone marrow cells and 
liver cells were then ready for subsequent experiments. 
       2.17 Western Blot analyses 
        Western blot analyses of the extracted histones were performed with enhanced 
chemiluminescence following standard protocols. Antibodies against mono-methyl 
(ab2886), di methyl (ab3594), and tri-methyl H3K79 (ab2621) were obtained from 
Abcam Inc. Antibodies against unmodified histone H3 and methylated histone H3 at 
lysines 4, 9, 27, and 36 were all obtained from Cell Signaling Technologies.  
Western blot analyses of TRPC6 from different tissues were performed following 
standard protocols. Cells from yolk sac, bone marrow or liver were lysed in Nonidet-P40 
buffer on ice for 30 minutes. The lysates was centrifuged at 12000 rpm at 4°C for 20 
minutes. Supernatant was collected and protein concentration was measured using 
Pierce BCA protein assay kit (Thermo Scientific). Protein was mixed with NuPAGE 
LDS 4X sample buffer (Life Technologies) and heated at 95°C for 5 minutes. Protein 
samples were loaded onto a 10%, 30ul BioRad precast gel (Bio-Rad) and run at 100V for 
45 minutes. PVDF (positively charged nylon) was soaked in Methanol for 1 minute and 
then transferred to cold transfer buffer for 3-5 minutes. Gels were taken out and 
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equilibrated in transfer buffer for 5 minutes. A transfer sandwich was created on Saran 
wrap and put into the transfer apparatus for transfer at 400mA for 4 hours. After transfer, 
the PVDF membrane was blocked in 5% BSA for 30-45 minutes. The membrane was 
then incubated with 1:500 mouse anti-TRPC6 primary antibody (Abcam, mAbcam63038) 
or 1:2000 mouse anti beta actin primary antibody (Abcam, mAbcam 8224) for 4 hours at 
4°C with shaking. Then the membrane was washed 5 times with TBST buffer at 4°C with 
shaking. The membrane was incubated with 1:5000 secondary antibody (Goat anti mouse 
IRDye CW800) for 45 minutes at 20°C. The membrane was washed another 5 times with 
TBST. The image was developed with Odyssey CLx infrared image system (LI-COR 
Biosciences) following the instructions of the manufacturer.  
        2.18 Chromatin immnoprecipitation (ChIP) assay 
         G1E cells, bone marrow cells or liver cells were used in my study. For each assay, 
10X106 cells were resuspended in 10ml IMDM medium containing 5% FBS. 270ul 37% 
Formaldehyde was added (final concentration 1%) and the cells were incubated at 37°C 
for 10 minutes. 540ul 2.5M glycine was added (final concentration 0.125M) and the cells 
were incubated at room temperature with rotation for 10 minutes. The cells were washed 
twice with PBS and transferred to a new 15ml tube. 500ul SDS lysis buffer with protease 
inhibitor was added and the cells were kept on ice for 10 minutes. The lysate was 
sonicated with Branson Sonifier 250 Analog Ultrasonic Homogenizer (Branson 
Ultrasonics) 15 seconds for 4-6 times to reduce DNA length to between 200 and 1000bp. 
The lysate was centrifuged at maximum speed at 4°C for 10 minutes. Clear supernatant 
was removed to another 1.5ml tube (can be stored at -80°C until use). To reduce 
nonspecific background, the chromatin solution (about 500ul) was precleared with 75ul 
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Protein A Agarose/Salmon Sperm DNA and incubated at 4°C with rotation over night. 
The solution was centrifuged 3000rpm for 5 minutes. The supernatant was transferred to 
a new tube and diluted 10 fold in ChIP Dilution Buffer. 1ml of the chromatin solution 
was used as “input”. Antibodies for H3K79me, H3K79me2, and H3K79me3 were 
purchased from Abcam Inc. Normal rabbit serum (Biosource international) was used as 
negative control. For each reaction, 2ug antibody was added to 1ml of chromatin solution 
and was incubated at 4°C with rotation for 4 hours. The chromatin solution was mixed 
with 65ul Protein A Agarose/Salmon Sperm DNA and incubated at 4°C with rotation for 
2 hours. The solution was centrifuged at 3000rpm for 5 minutes at 4°C and supernatant 
was discarded. The Protein A agarose beads were washed for 3-5 minutes on a rotating 
platform sequentially with 1ml of each of the buffers listed below: 
       Low Salt Immune Complex Wash Buffer 
       High Salt Immune Complex Wash Buffer 
       LiCl Immune Complex Wash Buffer 
       1XTE 
       1XTE 
       250ul elution buffer was added to the beads. The beads were vortexed briefly and 
were incubated at room temperature for 15 minutes with rotation. The beads in elution 
buffer were centrifuged and supernatant was carefully transferred to another tube. The 
elution process was repeated and elutes were combined. 20ul 5M NaCl was added to the 
combined eluates and crosslinks were reversed at 65°C for 4 hours. 10ul 0.5M EDTA, 
20ul 1M Tris-HCl, pH6.5, and 2ul 10mg/ml Proteinase K were then added to the eluate 
mix and incubated at 45°C for 1 hour. The DNA was recovered by phenol/chloroform 
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extraction and ethanol precipitation. Real-time PCR was performed to quantify 
precipitated DNA with the use of the Applied Biosystems 7500 real-time PCR system. 
Primer pairs for analyzing the Trpc6 locus, Gata-2 locus, and pu.1 locus were designed 
with MacVector software (MacVector Inc.) and are listed below:  
Primer sequences for Trpc6 locus 
Trpc6 promoter1: 
5’-AAG CAG GGC TCA CTG AAT CTG G-3’  
5’-GGC ATT TTC CGA TGG TGT CTG-3’ 
Trpc6 promoter2:  
5’-CCC AAA TAA AGA ATG TGC CTG G-3’ 
5’-CGC TGA AGA GTT ACT ATG TCA ACC G-3’ 
Trpc6 TSS:  
5’-GAG AGC CAG GAC TAT TTG CTG ATG-3’ 
5’-TGC CCT CGC CCA TAC TTA CAA G-3’ 
Trpc6 Middle: 
5’-TCT ACC TCC TGA TGC TGG GCT TAC-3’ 
5’-GGG GTT TGA AGA GAT GAG AGT GC-3’ 
Trpc6 End: 
5’-TGC CCT ACA AAG CAA TGA AAG G-3’ 
5’-AAA GAG AGC GTG AGC CCA ACA C-3’ 
 
 Primer sequences for Gata-2 locus:  
1S promoter:  
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5'- GCATAACGGTGTGTCTGAAAGGAG -3'  
5'- GGATGTAATCTCTGAAAGCCTGCG -3’  
1G promoter:  
5'- TTCCCTCTCCCTAAAGACCGTC -3’  
5'- TAGTAGACCACCAGGCTGAACTGC -3’  
1S exon:  
5'- CGGAGTCGGAATCTTTTCAGTGG -3’  
5'- CGAATGGTTCAATGCCCAGC -3’  
1G exon:  
5'- TCTTATGCTTTGGGGAGAGGTTG -3'  
5'- ACACGGATAGGTCCTGACATCG -3’  
Intron4:  
5’-GACATCTGCAGCCGGTAGATAAG  
5’-CATTATTTGCAGAGTGGAGGGTATTAG’  
Primer sequences for pu.1 locus:  
5’URE:  
5'- GCC CAG GCT AGG GAA GTT TG -3'  
5'- GAG AGC AGA GCA CTT CAT GGC TA -3'  
3’URE:  
5'- GGG AGG CAG AGC ACA CAT G -3'  
5'- GTT TCC ACA TCG GCA GCA G -3'  
Promoter:  
5'- GTA GCG CAA GAG ATT TAT GCA AAC -3'  
	 63
5'- GCA CAA GTT CCT GAT TTT ATC GAA -3' 
        2.19 Flow cytometric analysis and fluorescence activated cell sorting 
        In order to analyze the progenitor population in yolk sac cells, single cell 
suspensions from yolk sac were incubated with anti-c-Kit antibody conjugated to 
phycoerythrin cyanine 5.5 (eBioscience Inc) and anti-CD41 antibody conjugated with 
phycoerythrin (eBioscience Inc) at 4°C for 30 minutes. The cells were washed with 
FACS buffer twice and resuspended in 200ul FACS buffer for flow cytometry analysis 
using BD Accuri® C6 Flow Cytometer. In some experiments, the progenitor population 
among yolk sac cells were analyzed by staining with anti-c-kit antibody and anti-CD45 
antibody conjugated with fluorescein isothiocyanate (BD Pharmingen). 
In order to obtain the enriched progenitor cells from yolk sac, single cell suspensions 
from yolk sacs were incubated for 30 minutes at 4°C with anti-c-kit antibody conjugated 
with phycoerythrin cyanine 5.5 (eBioscience Inc). The c-kit positive cells were isolated 
by cell sorting with the use of a BD FACSAria cell sorter (BD Biosciencys). Sorted cells 
were either cultured for colony-forming unit assays or used for gene expression studies.   
       2.20 Measure calcium concentration changes in yolk sac cells in 
response to EPO 
        A fluorescence microscopy-coupled digital imaging system was used to measure 
calcium concentration change of whole yolk sac cells when the cells were treated with 
EPO. Fura2 (Invitrogen) was used as the detection fluorophore. 50mm culture dishes (BD 
Biosciences) were coated with poly-lysine (Sigma) for 10 minutes at room temperature 
and then air-dried. After the yolk sacs were dissociated into single cells, the cells were 
washed with PBS 3 times to completely remove FBS. The cells were resuspended in 40ul 
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RPMI 1640 (Sigma) without FBS and were loaded into the center of a culture dish coated 
with poly-L-lysine. The cells were fixed for 10 minutes at room temperature without 
shaking or moving. The medium was aspirated carefully without touching yolk sac cells 
attached to the bottom. A mixture of 1uM Fura2 and pluoronic F127 (Invitrogen) (1:1 in 
volume) was added on top of the cells and the cells were stained at 37°C for 30 minutes. 
The staining solution was removed and the cells were covered with 150ul RPMI 
containing 10% FBS. At the beginning of the experiment, mouse EPO (R&D systems) 
was added at a final concentration of 10unit/ml. The sample was analyzed immediately 
with the confocal fluorescence microscopy on a Nikon TE2000U microscope. Fura2-
loaded cells were visualized with digital video imaging and fluorescence was quantified 
using the fluorescence intensity ratio of the emission (510nm) measured following 
excitation at 340nm divided by the emission following excitation at 380nm. Calcium 
responses from cells in each sample were measured for 20 minutes. Finally, the data was 
calculated and analyzed by Metamorph6.1 (Universal Imaging Corp., Downington, PA).  
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Chapter 3 
Early mammalian erythropoiesis requires the DOT1L 
methyltransferase 
          3.1 Introduction  
           Among the first differentiated cell types to emerge in the developing mammalian 
embryo are the blood cells. In the mouse, the process of blood development, 
hematopoiesis, begins at approximately embryonic day 7.0 to 7.5 (E7.0-E7.5), when cells 
originating at the primitive streak migrate to the site of yolk sac formation.120 By E7.5, 
the cells coalesce into blood islands, where they mature, proliferate, and differentiate22. 
These early hematopoietic progenitors, termed primitive erythroid colony-forming cells, 
are nucleated red cells, which express primitive globins and can carry oxygen to nourish 
the developing embryo on the initiation of blood flow after E8.528,120-122. The presence of 
these primitive progenitors is transient, peaking in numbers at E8.0 and disappearing by 
E9.0, whereas the progeny erythrocytes persist throughout gestation24. After E8.5, a 
second wave of hematopoietic progenitors emerges from a variety of sites, including the 
vasculature about the aorta-gonad-mesonephros and the yolk sac. These cells enter the 
circulation and migrate to the developing fetal liver. There, they proliferate and undergo 
“definitive” maturation, giving rise to multiple adult hematopoietic lineages, including 
mature, enucleated erythrocytes1. This multi-step process of hematopoiesis and the fate 
decisions of the developing cells are regulated by the precisely controlled, sequential 
induction and silencing of gene expression in response to a variety of growth and 
differentiation factors5. The identity of the cell-type specific genes that direct 
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differentiation, the factors controlling their expression, and the mechanisms by which 
their expression is regulated are currently active areas of investigation. 
            Although many mechanisms probably contribute to the coordination of gene 
expression during hematopoiesis, it is becoming increasingly clear that epigenetic change 
is an important strategy used by eukaryotes to accomplish such complex regulation123-125. 
One of the most widely studied regulators of epigenetic change is the enzymatic 
modification of histones. In eukaryotic cells, histones and histone-associated proteins 
along with DNA are packaged into nucleosomes, which are the fundamental repeating 
structural units of chromatin126. The histones can be posttranslationally modified in a 
variety of ways, including acetylation, phosphorylation, ubiquitination, and methylation. 
These modifications influence chromatin structure, facilitate interactions between 
nucleosomes, recruit non-histone proteins to the DNA, and can potentially regulate 
transcription10. 
            Histone methylation has been shown to play an important role in regulating both 
chromatin function and gene expression. Most histone lysine methyltransferase (HLMT) 
family members contain a conserved SET domain, which is required for enzymatic 
activity and believed to be a signature motif for this class of enzymes10,104,127. One 
member of this family that is an exception to this rule is disruptor of telomere silencing 1 
(DOT1), an HLMT first identified in Saccharomyces cerevisiae97. Unlike other HLMT, 
DOT1, as well as its mammalian homologue DOT1-like (DOT1L), lacks a SET 
domain97,126. Further, the substrate residue for DOT1/DOT1L is lysine 79 of histone H3 
(H3K79), which is not located on the N-terminal tail of H3, but rather is located within a 
loop in the globular domain of the histone that is exposed on the nucleosome surface89. 
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These unique aspects of Dot1L may underlie the distinctive biologic roles that have been 
identified for this enzyme relative to other HLMTs11,126,128. The consequences of H3K79 
methylation are incompletely understood, but this histone modification has been shown to 
be strongly associated with actively transcribed chromatin in several mammalian cell 
lines13.  
            A mouse line was established by another group, in which DOT1L activity was 
disrupted by targeted mutation. This study focused on the embryonic development of 
Dot1L knockout (KO) mice, DOT1L function in embryonic stem (ES) cell growth, and 
aberrant telomere elongation in Dot1L KO ES cells12. Defects in yolk sac angiogenesis 
were reported, but no alterations in hematopoiesis were described. In other studies, 
however, H3K79 methylation was observed in the -globin locus, suggesting a possible 
role for this histone modification in erythropoiesis129,130. To date, no detailed molecular 
level studies of the role of DOT1L in hematopoiesis have been carried out.   
            A mouse line in which a gene trap has been used to abrogate DOT1L activity was 
created in our laboratory7. After analysis of the mouse line, we confirmed that DOT1L 
function is essential for embryogenesis, with embryonic lethality occurring at mid-
gestation in Dot1L deficient mice. Notably, we observed a defect in early erythropoiesis 
as a primary contributor to this embryonic lethality. This work highlights the importance 
of H3K79 methylation in embryogenesis and has begun to shed light on DOT1L function 
in embryonic hematopoiesis. 
            3.2 Results 
            3.2.1 Generation of mouse lines containing mutant allele of Dot1L   
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            To generate an in vivo model of deficient Dot1L function in the mouse, an ES cell 
line was obtained from Bay Genomics with an insertion mutation in the Dot1L locus. 
Four primers were designed to determine the exact position of the gene trap insertion. 
Three forward primers were within intron 11 of the Dot1L gene (F1, F2, F3), whereas the 
reverse primer was within the inserted gene trap (R1) (Figure3.1 A). Sequence analysis 
identified the gene trap cassette within exon 13 after the 26th nucleotide. This position is 
5’ to the region encoding the critical nucleosome-binding region of DOTL (amino acids 
390-407), which is essential for DOT1L enzymatic activity13. Thus, insertion in this area 
would be predicted to result in a substantial disruption of DOT1L function. Indeed, this 
gene trap has been used recently to analyze DOT1L loss of function in fibroblasts13. 
Embryos were generated with gene-trapped stem cells, and genotyping PCR primers were 
used to distinguish wild-type (WT), Dot1L heterozygous mutant, and KO mice and 
embryos (Figure3.1 B).  
To assess the functional consequences of DOT1L loss, MEF were derived from WT, 
heterozygous, and homozygous mutant (KO) E10.5 embryos. In MEF from Dot1L-KO 
embryos, there was no significant expression of Dot1L mRNA (Figure3.2). Because 
antibodies were not available to measure protein expression, DOT1L activity was 
assessed by analyzing H3K79 methylation. Histones were prepared from each genotype, 
and immunoblot analysis showed that mono-, di-, and tri-methylation of H3K79, the 
reported substrate for DOT1L89, were completely abrogated in the KO MEF, whereas in 
both WT and heterozygous MEF, H3K79 methylation was unaffected (Figure3.1 C). The 
patterns of H3K79 methylation were not influenced by either presence or absence of 
serum (Figure3.1 C, compare left with right panels), conditions known to influence  
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Figure 3.1. Generation of mice with 
mutant Dot1L alleles. (A) Schematic 
representation of the “gene trap” construct 
used to generate the mutant Dot1L alleles 
(KO). The numbered boxes represent exons 
of the Dot1L gene. Arrows represent PCR 
primers used to amplify DNA from ES cells 
to identify the exact point of insertion of the 
gene trap. (B) PCR genotyping using DNA 
from embryos generated by interbreeding 
heterozygous Dot1L mutant mice. PCR 
primers were generated that distinguished 
WT and KO alleles. As expected, both alleles 
were detected in heterozygous embryos (lane 
3). (C) Absence of H3K79 methylation in 
MEF from Dot1L-/- embryos. MEF were 
derived from E10.5 embryos and either serum-starved for 24 hrs. (left bands) or treated 
overnight with 20% FCS (right bands). Histones were acid-extracted from cells and 
proteins were resolved by SDS-PAGE. Blots were probed with antibodies against histone 
H3 Lysine 79 mono- (H3K79me), di- (H3K79me2), and tri-methylation (H3K79me3). 
Other antibodies against Histone H3 modifications were used to probe the blot including: 
unmodified Histone H3 (H3), dimethylated lysine 4 (H3K4me2), dimethylated lysine 9 
(H3K9me2), dimethylated lysine 27 (H3K27me2), and lysine 36 (H3K36me2). 
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Figure 3.2 Dot1L expression levels in WT, heterozygous, and Dot1L KO cells: 
RNA was extracted from WT, HET, and Dot1L KO mouse embryonic fibroblast cells 
(MEFs), converted into cDNA, and Dot1L expression was measured by Real-Time PCR. 
Average value for WT cells was normalized to 1 and HET and KO values were 
calculated. Error bars represent standard deviation of calculated values from five (WT), 
four (Het), and 14 (KO) independent cell lines.  
Primer sequences: 
Forward: GGC CCA AAA GGA AGA AAA TCC 
Reverse: TCA GGT CAT TGT AGG TCA GC 
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histone methylation. Other H3 lysine methylation marks, including di-methylation of K4, 
K9, K27, and K36, were unaffected in mutant MEF (Figure3.1 C). These results confirm 
that DOT1L is specific for H3K79 and is the only detectible H3K79 methyltransferase 
during embryogenesis, consistent with previous reports12,89.  
         3.2.2 Dot1L deficiency results in embryonic lethality and severe anemia 
         The Dot1L heterozygous mice appear phenotypically normal and fertile. However, 
on examination of more than 150 pups, no viable Dot1L KO offspring were produced 
after breeding heterozygotes (Table 3.1), indicating that Dot1L deficiency resulted in 
embryonic lethality. To identify the timing and cause of the Dot1L KO-dependent 
lethality, WT, heterozygous, and KO embryos were examined at several time points 
during development. The genotype distribution at E9.5 occurred at expected Mendelian 
ratios, and there were no distinguishable phenotypic differences between WT, 
heterozygous, and KO embryos harvested from the litters at this time point. At E10.5, the 
distribution of viable embryos was close to the expected Mendelian ratios, but most KO 
embryos were reduced in size compared with WT littermates (Figure 3.3 A-B). In 
addition, Dot1L KO embryos exhibited a striking near absence of red blood cells, which 
resulted in an overall paler appearance than the WT embryos (Figure 3.3 C-D). 
           Examination of the yolk sacs showed that those from KO embryos also contained 
less blood and exhibited altered vessels in comparison to the yolk sacs from WT embryos 
(Figure 3.3 E-F). Immunofluorescence analysis of WT and KO yolk sacs with the use of 
anti-platelet endothelial cell adhesion molecule (CD31) showed that both contained 
abundant endothelial cells, which constitute the complex vascular plexus network present 
at this time. In WT yolk sacs at E10.5, progression of angiogenic remodeling was  
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Figure 3.3 Defects in hematopoiesis and vascular development in Dot1L KO 
embryos.  
 (A-B) Representative pictures of WT (A) and 
Dot1L KO (B) embryos at E10.5, showing reduced 
embryo size as well as significant anemia in the 
Dot1L knockout embryos. Note the overall pale 
appearance of the knockout embryo. (C-D) 
Representative pictures of whole mount WT (C) and 
Dot1L KO (D) embryos with surrounding yolk sac 
show that yolk sacs from Dot1L KO contain less 
blood and exhibit a reduction in the number of 
vessels compared to those from WT. A-D were 
viewed using a NIKON SMZ800 stereo microscope 
with Plan 1X objective lenses (total 10X) and 
images were taken with a LEICA DFC480 camera 
using Leica Firecam software at room temperature. (E-F) Representative enlarged 
pictures (20X) reveal that blood vessels in KO yolk sacs exhibit abnormal caliber and 
contain less blood compared to WT. (G-H) Representative immunofluorescence confocal 
images of E10.5 yolk sacs stained with anti-CD31 show a mild defect in vascular 
remodeling in the Dot1L KO embryos (H). Pictures are representative of 7-10 individual 
embryos. Pictures were viewed with an Olympus 1X71 microscope with 10X UPLANF1 
objective lens and images were taken by Olympus DP71 camera using Olympus DP71 
controller software. The fluorochrome was FITC. 
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observed, as indicated by the large caliber vessels of the vitelline artery and vein. In 
Dot1L KO yolk sacs, the remodeling process was present; however, the vessels appeared 
disorganized and exhibited relatively deficient vascular branching, similar to the Dot1L-
deficient yolk sacs described by Jones, et al12. (Figure 3.3 G-H) 
            At E11.5, the percentage of viable Dot1L KO embryos was much lower than the 
expected Mendelian ratio, and no KO embryos survived at or beyond E13.5 (Table 3.1). 
Collectively, these data show that the Dot1L KO embryos do not survive past mid-
gestation, a phenomenon probably due to the severe anemia and associated defects in 
vascular remodeling.  
            3.2.3 DOT1L controls yolk sac erythropoiesis 
            The severe anemia observed in the KO embryos suggested that DOT1L is 
essential for hematopoiesis. Because it is thought that a primitive erythroid defect would 
contribute to anemia observed before E131,26, we first investigated whether the loss of 
DOT1L affects the formation of primitive erythroid progenitor cells. At E10.5, most 
circulating, differentiated erythroid cells should be derived from primitive 
erythropoiesis1. A non-quantitative analysis of blood smears at this time point showed 
normal appearing, nucleated erythroid cells in the Dot1L KO embryos of various stages 
of maturation (Figure 3.4). We carried out more quantitative CFU assays to determine the 
ability of primitive progenitors to proliferate and form colonies in response to growth 
factors. With the use of E8.5 embryos and yolk sacs as a source of primitive erythroid 
progenitors, we found that the Dot1L KO cells gave rise to significantly fewer colonies 
when we applied equal numbers of the cells onto each culture dish (Figure 3.5 A). In 
addition, with the use of image analysis, we observed that Dot1L KO colonies were only  
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Figure 3.4 Blood smears of circulating blood from E10.5 embryos: 
Circulating blood from E10.5 embryos was collected in capillary tubes and smears were 
visualized by Giemsa staining. Pictures were viewed using a NIKON ECLIPSE 55i 
microscope with NIKON Plan 40X, numerical aperture 0.17 objective lens and were 
taken with a LEICA DFC480 camera equipped with Leica Firecam software. No 
morphological differences are observed. Photos are representative of smears analyzed 
from 6 WT and 4 KO embryos.  
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Figure 3.5 Loss of DOT1L results in the impairment of both primitive and definitive 
yolk sac erythropoiesis. (A-B) Identical numbers of dissociated E8.5 yolk sac cells were 
cultured for 7 days in media specifically supporting the outgrowth of primitive erythroid 
colonies. Colonies were enumerated (A), and size was measured (B) with ImageJ 
software. (C-D) Identical numbers of dissociated E10.5 yolk sac cells were cultured in 
methylcellulose growth medium supporting both erythroid and granulocyte-macrophage 
progenitors. Colonies were scored and counted (C) after 10-12 days in culture. (D) The 
area of single BFU-E and CFU-GM colonies was measured to estimate colony size with 
ImageJ software. (E) Identical numbers of dissociated E10.5 yolk sac cells were plated in 
methylcellulose medium that only supports the outgrowth of erythroid progenitors (CFU-
E and mature BFU-E). Colonies were identified and counted after 3 days of culture. (F) 
C-kit+ cells were isolated from individual yolk sacs by sorting. Identical numbers from 
each genotype were cultured in methylcellulose medium containing erythropoietin for 10 
days. Total erythroid colonies were enumerated. (G-L) Representative pictures of 
primitive erythroid (G-H), BFU-E (I, J), and CFU-GM (K-L) colonies showing size and 
appearance differences between WT (G, I, K) and Dot1L KO (H, J, L). Figure G-H are 
derived from experiments described in Figure 3A-3B. Figure I-L are from the experiment 
described in Figure 3C-3D. Cultures were viewed with a NIKON ECLIPSE TS100 
microscope. Images were taken with a LEICA DFC480 camera using Leica Firecam 
software in room temperature. *average number (A, C, E) and size (B, D, F) of KO 
colonies was significantly different from WT and heterozygotes (p<0.01; t-test) Error 
bars represent standard errors within each group. 
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approximately one half the average size of WT or heterozygous colonies (Figure 3.5 B, 
G, H; P.01) 
           We next analyzed definitive hematopoiesis at E10.5, when the anemic phenotype 
of Dot1L KO embryos is obvious, but embryonic viability remains unaffected. At this 
time, the fetal liver is not yet completely developed, and a substantial reservoir of 
embryonic hematopoiesis occurs in cells derived from the yolk sac1,17. Yolk sacs from 
E10.5 embryos were dissociated and plated under conditions that support multipotent, 
erythroid and myeloid progenitor cell differentiation. The number of definitive erythroid 
progenitors was measured by counting BFU-E colonies, which have a characteristic 
structure under light microscopy (Figure 3.5 I). The total number of BFU-E colonies 
obtained from KO yolk sac cells was much lower than the number obtained from WT or 
heterozygous embryos (Figure 3.5 C). In contrast, the number of CFU-GM was not 
significantly different among WT, heterozygote, and KO yolk sacs (Figure 3.5 C). The 
few BFU-E colonies generated from Dot1L KO yolk sacs were approximately 3 times 
smaller than WT colonies, suggesting that Dot1L-deficient erythroid progenitors are 
defective in their ability to optimally proliferate in response to growth factors in the 
media (Figure 3.5 D, I, J; P.01). No significant difference in the size of the CFU-GM 
colonies was observed among the different genotypes (Figure 3.5 D, K, L). 
            We next plated equal numbers of dissociated yolk sac cells on medium that only 
supports the outgrowth of erythroid CFU colonies (Figure 3.5 E). Under these conditions, 
significant fewer KO erythroid colonies were derived than from either WT (P0.01) or 
heterozygous (P0.02) cells. The slight difference between WT and heterozygous colony 
numbers was not statistically significant (P=0.38). Primitive and definitive WT and  
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Figure 3.6 Benzidine staining of primitive and definitive erythroid colonies: 
Benzidine staining was performed on primitive erythroid colonies derived from E8.5 yolk 
sacs (A, B) and BFU-E colonies derived from E10.5 yolk sacs (C, D). Both WT and 
Dot1L KO showed positive staining, although in WT colonies, the staining was more 
intense than in Dot1L KO cells, due to much greater cell numbers in each colony. Stained 
colonies were viewed with a NIKON ECLIPSE TS100 microscope equipped with 20X 
phase contrast, numerical aperture 1.2 objective lens. Images were taken with LEICA 
DFC480 camera using Firecam software in room temperature.  Shown are representative 
pictures of primitive colonies derived from 4 WT and 3 KO embryos and definitive 
colonies from 5 WT and 3 KO. 
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Dot1L KO erythroid colonies were all positive for benzidine staining, indicating normal 
globin production in the KO cells. However, the staining was less intense in KO colonies, 
because of relatively lower cell numbers in each colony (Figure 3.6). We also collected 
cells from primitive and definitive erythroid colonies and analyzed them by Giemsa 
staining. No gross structural differences between WT and Dot1L KO were observed at a 
single-cell level (Figure 3.7).  
          The observed defect in erythropoiesis could be from either a reduction in the 
relative number of erythroid progenitors or a reduction in the developmental potential of 
these cells that are present. Hematopoietic progenitors in the yolk sac are enriched within 
the CD41+/c-kit+ population19. Thus, we analyzed CD41+/c-kit+ frequency in E10.5 
embryos. No significant differences were observed in the relative percentages of these 
populations between WT and KO yolk sacs, although the absolute numbers of cells were 
lower (Figure 3.8). Likewise, we detected no differences in the percentages of total 
CD45+/c-kit+ cells in yolk sacs (Figure 3.9). Therefore, the definitive progenitors in 
Dot1L KO yolk sacs emerge relatively normally.  
         C-kit is expressed by most common hematopoietic progenitor cells, including those 
that give rise to erythrocytes. Identical numbers of sorted, c-kit+ yolk sac cells from each 
genotype were cultured under conditions that support both erythroid and myeloid 
differentiation. After 10 days of culture, no BFU-E colonies developed from KO c-kit+ 
yolk sac cells, whereas myeloid colonies (CFU-GM) formed normally (Figure 3.5 F). In 
contrast, c-kit+ progenitors from WT and heterozygous tissues formed BFU-E and CFU-
GM colonies as expected. 
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Figure 3.7 Giemsa staining of cells from WT and KO primitive and definitive 
erythroid colonies: 
Cells from WT or Dot1L KO primitive (A,B) and definititve (C,D) erythroid colonies 
were collected in 3 ul PBS, smeared onto microscope slides and visualized by Giemsa 
staining. Pictures were viewed using a NIKON ECLIPSE 55i microscope with NIKON 
Plan 40X, numerical aperture 0.17 objective lens and were taken with LEICA DFC480 
camera equipped with Leica Firecam software. Pictures are representative stains of 6 WT 
and 3 KO primitive colonies and 4 WT and 3 KO definitive colonies. 
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Figure 3.8 C-kit/CD41 staining of E10.5 yolk sacs from WT and Dot1L KO 
embryos: 
Yolk sacs were collected and dissociated to single cells, and then stained with CD41 and 
c-kit antibodies. The frequency of double positive cells was similar between WT and 
Dot1L KO yolk sacs (A). Representative figures for WT (B) and Dot1L KO (C) are 
shown.  
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Figure 3.9 c-kit+/CD45+ cells in E10.5 yolk sacs: 
Table showing average percentages of c-kit+, CD45+, and double positive cells in Dot1L 
WT, HET, and KO yolk sac cells from single embryos. Numbers represent average + 
SEM for each genotype. 
 Representative histograms of wildtype, heterozygous, and homozygous mutant FACS 
staining of total yolk sac cells for c-kit and CD45. 
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            3.2.4 Dot1L deficiency blocks cell-cycle progression and promotes apoptosis of 
hematopoietic progenitor cells 
          Defective erythropoiesis in the Dot1L KO could result from either an alteration in 
cell-cycle progression or increased apoptotic death of progenitor cells or both. To 
distinguish between these possibilities, we plated cells from individual E10.5 yolk sacs 
on erythroid growth media for development into erythroid colonies. After 4 days of 
growth, we harvested the cells and analyzed their cell-cycle profile by propidium iodide 
staining and flow cytometry. An analysis of 7 WT and 8 KO embryos showed a 
significant defect in the KO cells’ progression through the cell cycle. We found in WT 
colonies, an average of 66% of cells were in G0/G1 stages, whereas 20% and 14% of cells 
were in S and G2/M stages, respectively. In sharp contrast, 82% of KO cells were found 
to be in G0/G1 stages, whereas 10% and 8% of the cells had progressed to S and G2/M 
stages (Figure 3.10 A).  
           We also examined apoptosis by annexin V staining in E10.5 yolk sac cells. After 3 
days of culture in erythroid growth media, Dot1L KO cells showed significantly more 
apoptosis than either WT or heterozygous cells (Figure 3.10 B). These data indicate that 
DOT1L loss in yolk sac-derived, erythroid progenitors induces both an increased G0/G1 
period and an increased susceptibility to apoptosis. We postulate that the requirement for 
DOT1L in timely cell-cycle progression and survival of the erythroid lineage may be 
partly responsible for the reduced number and size of erythroblast colonies generated by 
KO yolk sacs and may contribute to the anemia observed in vivo. 
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Figure 3.10 Defects in cell cycle progression and increased apoptosis caused by 
Dot1L knockout during erythropoiesis. (A) Dissociated yolk sac cells of wildtype and 
Dot1L knockout embryos were plated in methylcellulose growth medium supporting 
erythroid lineage growth and cultured for 4 days. The cells were harvested and cell cycle 
was analyzed by PI staining and flow cytometry. Differences in percentages of cells in all 
stages of the cell cycle were significantly different (p<0.02; t-test) (B) Analysis of 
apoptosis in examined in yolk sac cells cultured in erythropoietin-containing growth 
medium by Annexin V staining and flow cytometry. 
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        3.3 Discussion 
        Due to the special position of lysine 79 on histone H3 and the unique structure of its 
methyltransferase—DOT1L, we sought to examine the effects of a germline KO of the 
Dot1L gene on embryonic growth and development. While these studies were ongoing, 
another group showed that DOT1L loss resulted in embryonic lethality12. That group 
showed that by E10.5, the viability of Dot1L KO embryos was the expected Mendelian 
ratio and that no KO embryos survived beyond this time. The lethality in these embryos 
was mostly ascribed to defective yolk sac angiogenesis. We observed similar defective 
yolk sac angiogenesis in Dot1L KO embryos. However, because we also observed a 
selective and profound defect in erythropoiesis, we propose that the vessel-remodeling 
defects observed in the Dot1L-mutant extraembryonic tissues are largely a consequence 
of altered hematopoiesis and reduced blood flow in these embryos. Indeed, an essential 
role for blood flow and hemodynamic forces in driving angiogenic remodeling of the 
yolk sac has been shown previously122.  
            Although Dot1L deficiency also resulted in embryonic lethality in our hands, our 
embryos survived somewhat longer than was reported in study mentioned earlier. In 
contrast to that study, we found that at E10.5 embryo viability appeared normal. 
However, most KO embryos were reduced in size compared with WT littermates, and no 
Dot1L KO embryos survived at or beyond E13.5. We believe this discrepancy may be 
due to the different methods used to generate the mutant embryos. The mutant described 
by Jones, et al. was generated by deletion of exons 5 and 6 of Dot1L12, whereas the gene 
trap mutation used in our studies resulted in an interruption of entire 3’ of the gene, after 
exon 13. 
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          Despite the differences in the generation of the KO, both Jones, et al. and our 
findings show that Dot1L KO results in the absence of H3K79 mono-, di-, and tri-
methylation. Notably, the conclusion of Jones, et al12. about the absence of mono-methyl 
H3K79 was based on mass spectrometry rather than immunoblot analysis, which was the 
basis of our conclusion. This was because the mono-methyl H3K79 antiserum reportedly 
cross-reacted with histone H3 in their hands. In our studies, this antiserum worked well 
for Western Blotting, was specific, and had minimal cross-reactivity with histone H3 
(Figure 3.1 C). The reason for this difference is not clear; however, it may be related to 
batch-to-batch variability of this polyclonal rabbit antisera or variability in secondary 
antibodies or means of detection.  
            Another group also examined DOT1L loss of function with the use of the same 
gene trap used in our study13. However, we have determined that the gene trap insertion 
is within exon 13, rather than in intron 12, as was previously suggested13. In agreement 
with our results, that study also reported specificity of the mono-methyl H3K79 antisera 
without cross-reactivity with H3 by immunoblot. In contrast to our findings, that group 
concluded that mono-methyl H3K79 was increased in the Dot1L KO cells. This 
conclusion was based on ChIP analyses, which showed enriched mono-methyl H3K79 in 
certain loci. The reason for this difference is not certain, but it is tempting to speculate 
that this result could reflect some level of cross-reactivity of the antisera with formalin-
fixed H3 in the immunoprecipitations.  
          Our results clearly show that Dot1L deficiency results in a significant defect in 
erythrocyte development, manifested by the severe anemia observed in E10.5 Dot1L KO 
embryos. At distinct times during development, the yolk sac is a source of progenitor 
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cells for both primitive and definitive erythropoiesis1,22. Our colony forming studies on 
cells from E8.5 and E10.5 embryos showed that DOT1L loss caused a defect in erythroid 
progenitors derived from both the primitive and definitive lineages. Analysis of isolated 
c-kit+ progenitors at E10.5 indicates that this defect resides in this cell population (Figure 
3.5 F). Although the total number of erythroid progenitors was reduced in the KO 
embryos, the relative percentages of these cells appeared normal (Figure 3.8 and 3.9). 
This fact, coupled with direct visualization of blood at E10.5 (Figure 3.4), indicates that 
both primitive and definitive progenitors can be produced and can mature normally. 
However, their common impaired expansion and survival in colony-forming assays 
suggests a shared deficiency or inappropriate response to erythroid growth stimuli, 
resulting in failure to form large colonies in vitro and anemia in vivo54,131-133.  This 
putative altered response to growth factors is probably the primary cause of lethality in 
these embryos after E10.5. Collectively, these data indicate that DOT1L plays an 
essential role in the growth and differentiation of the erythroid lineage during early 
hematopoiesis. 
           As I discussed in the previous chapter, the primitive and definitive erythrocytes 
derived from yolk sac could only meet the needs of embryonic growth temporarily. The 
continuous generation of blood cells from long-term hematopoietic stem cells (HSC) is 
the ultimate aim of adult hematopoiesis1. The first long-term HSC, which have the 
capacity of engrafting adult recipients, could be identified in the AGM region at E10.530. 
HSC then migrate through the blood stream and seed the fetal liver at E11. Subsequently, 
the hematopoietic niche shifts gradually from the fetal liver to the bone marrow cavity 
and the fetal liver stops functioning as an hematopoietic organ soon after birth1,16. Since 
	 87
our Dot1L mutant mice suffer embryonic lethality at mid-gestation, we could not analyze 
DOT1L function in HSC using our mouse model. Soon after we reported our data, at 
least two other groups carried out studies on DOT1L function in adult hematopoiesis in 
mice15,115.  
         To circumvent embryonic lethality, an inducible Dot1L KO mouse line was 
generated. Dot1L conditional mice were crossed with a Cre-ER mouse line (R26-Cre-
ER), so that Dot1L can be deleted in vivo by Tamoxifen (TAM) injection. They 
performed real-time PCR to demonstrate that TAM treatment can induce Dot1L depletion 
efficiently. Only one week after injection, conditional KO mice showed signs of anemia 
and bleeding, while WT control group appeared normal. Consistent with our 
observations, a general hypocellularity in the bone marrow of conditional KO mice was 
observed when compared with WT controls115. By doing flow cytometry and bone 
marrow transplantation experiments, both these two groups proved that DOT1L is critical 
in maintaining normal adult hematopoiesis and that depletion of DOT1L leads to bone 
marrow failure15,115.  
             The DOT1L studies in adult mice are very good extensions of our work, and 
supplement our DOT1L studies in embryonic development. Indeed, both of them 
demonstrated a critical role for DOT1L in maintaining normal adult hematopoiesis in 
mice. However, their results are not completely consistent with our research. In our 
research, the emergence of a progenitor cell population was not significantly affected by 
Dot1L mutation, which was demonstrated by flow cytometric analysis of CD41/c-kit 
double stained and CD45/c-kit double stained E10.5 yolk sac cells. The percentage of 
double positive cells was almost the same between WT and the Dot1L KO group7. This 
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indicated that the progenitor cells could still emerge relatively normally in absence of 
DOT1L. But they could not proliferate and differentiate properly, possibly due to defect 
in their response to erythroid growth stimuli. In contrast, in the conditional Dot1L KO 
studies, they found that the percentage of multiple progenitors including CMP (common 
myeloid progenitors), GMP (granulocyte/monocyte progenitors) and MEP 
(megakaryocyte/erythrocyte progenitors) are reduced significantly in Dot1L KO mice 
compared with the WT mice15. Moreover, an interesting phenomenon in our research was 
that there was a specific defect in erythroid lineage development in Dot1L mutant yolk 
sac cells, while the myeloid lineage was not significantly affected7. However in the 
Dot1L conditional KO adult mice, both myeloid and erythroid lineages were significantly 
affected15. We speculated the possible explantions for the inconsistency. First, a different 
method was used to generate the Dot1L mutant mouse line. The conditional KO 
described by the other two groups was generated using the Cre-Lox system in which exon 
2 on Dot1l locus was inducibly deleted by addition of TAM. The gene trap mutation used 
in our research resulted in an interruption of entire 3’ of the gene, after exon 13.  
Therefore different protein products could be produced through different methods. The 
difference in protein structure could give rise to distinct biological effect. Second, it is 
possible that DOT1L plays distinct roles at different developmental stages. Maybe for 
hematopoiesis during embryonic development, DOT1L is mostly required for erythroid 
lineage development. The function of DOT1L in myeloid lineage development is 
marginal. However, for hematopoiesis in the adult stage, DOT1L may play a more 
extensive role in HSC, multipotent progenitors, and committed erythroid and myeloid 
progenitors. This different functionality at different stages could be achieved by 
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regulating the expression of different sets of genes. To test this possibility, genome-wide 
gene expression analysis in hematopoietic tissues in both embryo and adult should be 
carried out. By doing this, we will find out whether DOT1L plays different role by 
controlling expression of different genes at various stages. More attention should be paid 
on genes that are important for emergence of HSC and the transition from HSC to 
hematopoietic progenitor cells, and on genes that are important for lineage commitment 
determination, such as Scl, Runx1, Gata2, Pu.15,33,134.  
            Although anemia is very obvious and severe in Dot1L KO mouse embryos, it is 
not the only defect observed. Our group as well as other groups has also identified 
diverse impairments including growth retardation, yolk sac angiogenesis defects, and 
cardiac dilation7,12. In order to explore a role of DOT1L in the heart, a cardiac specific 
conditional KO mouse model has been generated. It was shown that loss-of-function of 
DOT1L in cardiomyocytes caused heart dilation and postnatal lethality, but DOT1L 
deficiency in the cardiac organ alone, was not sufficient to cause embryonic lethality114. 
It would be very interesting if hematopoietic-specific conditional KO mice could be 
established to analyze whether hematopoietic defect alone is responsible for the 
embryonic lethality. 
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Chapter 4 
Mechanistic studies of DOT1L in embryonic erythropoiesis 
            4.1 Introduction 
            Since our data clearly demonstrated that Dot1L deficiency results in an 
embryonic hematopoietic defect, specifically in the erythroid lineage, I next wanted to 
find out the possible mechanism(s) through which DOT1L plays its role in 
hematopoiesis. The differentiation of multi-potential hematopoietic progenitor cells into 
diverse blood cell types is intricately regulated by specific signaling stimuli and by 
complex transcriptional networks. Dysfunctional regulation of signaling pathways or of 
transcriptional programs can result in the development and progression of anemia and/or 
certain leukemias4,5. DOT1L and H3K79 methylation have been proposed to play a role 
in gene transcriptional regulation92. Both DOT1L and H3K79 methylation were found 
enriched at actively transcribed sites. A strong similarity between the patterning of 
H3K79 methylation and that of H3K4 methylation, another type of epigenetic 
modification associated with actively expressed genes, was identified in several 
mammalian cell lines, suggesting that parallel pathways may exist to specify gene 
activity or antagonizing gene silencing13. Therefore I initiated the mechanistic studies by 
analyzing the expression pattern changes of some important genes in hematopoiesis upon 
Dot1L mutation. 
             Previous studies indicated that although H3K79 methylation is a universal 
modification in the genome, only certain genes requires DOT1L for proper 
expression13,92,108. On the basis of observations across different species, it has been 
proposed that DOT1L is required by a subset of developmentally regulated genes. We 
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observed the same phenomenon in our gene expression analyses. Among more than 20 
genes that we studied, most of them were not affected by Dot1L mutation at a 
transcriptional level. Interestingly, we observed that the expression of two important 
transcription factors, Gata-2 and pu.1, were differentially regulated in Dot1L KO 
hematopoietic progenitor cells7. The relationship between Gata-2 and pu.1 expression has 
been characterized and established for many years. GATA family factors and PU.1 are 
lineage-specific transcription factors that are expressed in multi-potential progenitor cells. 
During lineage commitment, activation of specific transcription factors has been shown 
to direct precursor cells to a certain differentiation pathway. At the same time, regulators 
promoting other lineages should be inhibited to ensure normal lineage 
differentiation46,52,53. Pu.1 is critical for myeloid lineage development and it is essential to 
block pu.1 function for normal erythroid cell development50,53,54. Gata-2 and Gata-1 are 
important for erythroid lineage development. Both of these genes are repressed when 
progenitor cells go through a myeloid differentiation pathway, during which pu.1 is up-
regulated49,53. Based on previous data and our gene expression analysis, I came up with a 
first hypothesis about the mechanism through which DOT1L controls embryonic 
hematopoiesis. Experimental results with regards to this hypothesis will be discussed in 
the following sections.  
             Through gene expression analysis, I also found that the expression of Trpc6, the 
gene encoding a member of the transient receptor potential channels (TRPC) family, was 
dramatically reduced in Dot1L mutant progenitor cells, while other TRPC family 
members were not affected by Dot1L deficiency. In erythroid lineage cells, only Trpc2 
and Trpc6 are expressed85. The function of TRPC2 is to facilitate calcium influx in  
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Figure 4.1 Calcium influx in response to EPO. In mice, Trpc2 and Trpc6 are expressed 
in erythropoietic lineage. TRPC2 was shown to mediate calcium influx in response to 
EPO, whereas TRPC6, which interacts with TRPC2, suppresses the EPO-induced 
calcium influx. Thus, the TRPC2/TRPC6 ratio in the plasma membrane provides a 
mechanism by which the intracellular calcium can be precisely regulated. The expression 
change of either of TRPC2 or TRPC6 on the hematopoietic progenitor cells will change 
the proper ratio of these two factors on cell membrane. If this occurs, the progenitor cells 
will not be able to respond to EPO properly. The model was drawn based on the results 
from Chu et al, 200485. 
 
 
 
 
	 93
response to erythropoietin, an important signaling mechanism controlling the 
proliferation and differentiation of erythroid progenitors and precursors. The function of 
TRPC6 is to inhibit calcium influx through TRPC2. It has been proposed that the 
stoichiometry of expression of Trpc2 and Trpc6 may be an important mechanism for 
regulating calcium influx in erythroid cells in response to erythropoietin stimulation74,83-85 
(Figure 4.1). In Dot1L mutant progenitor cells, the expression of Trpc6 decreased, while 
Trpc2 remained unaffected. We propose that the normal ratio between these two protein 
factors has been disrupted upon Dot1L deficiency. Based on these previous data, a second 
hypothesis about how DOT1L plays its role in hematopoiesis was proposed and will be 
discussed in this chapter. These studies explored the possible mechanisms through which 
DOT1L regulates embryonic hematopoiesis and provide potential explanations for the 
hematopoietic defect in Dot1L deficient animals.  
           4.2 Results 
           4.2.1 Expression patterns of certain genes that are critical in hematopoiesis are 
changed in Dot1L mutant progenitor cells 
           To more precisely understand the mechanism by which DOT1L affects 
erythropoiesis, the expression levels of genes known to play important roles in erythroid 
development were examined in c-kit positive WT and KO E10.5 yolk sac cells. No 
significant changes in the expression of globin genes was observed in Dot1L mutant cells 
(Figure 4.2 A), which is consistent with positive benzidine staining of KO erythroid 
colonies (Figure 3.6). Remarkably, among the genes profiled by reverse transcription-
PCR, only five were significantly affected by DOT1L loss: Gata-2 and Trpc6, which 
were reduced; and pu.1, scf, and Trap220, which were all increased (Figure 4.2 B-D).  
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Figure 4.2. Gene expression analysis of wildtype and Dot1L knockout progenitor 
cells in yolk sac.  
mRNA was extracted from FACS-sorted, c-kit+ yolk sac progenitor cells. Reverse 
transcription was performed and genes known to be important in erythropoiesis were 
assessed by quantitative RT-PCR. mRNA was obtained from c-kit+, sorted cells from 3-
10 individual yolk sacs. (*p<0.01; t-test). 
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The Dot1L mutant c-kit+ hematopoietic progenitors showed a consistent elevation in pu.1 
level relative to WT, whereas Gata-2 expression was decreased by about 40% (Figure 4.2 
C). These data suggest that the maintenance of a normal ratio of Gata-2 to pu.1 is 
influenced by H3K79 methylation and are consistent with the reported reciprocal 
expression and functional relationship between Gata-2 and pu.1 within hematopoietic 
progenitors49,53.  
           Trpc6 expression in Dot1L mutant progenitor cells was reduced to about 30% of 
the WT level (Figure 4.2 D). TRPC6 is a calcium permeable non-selective cation channel 
expressed in brain, smooth muscle containing tissues, as well as hematopoietic cells. It 
belongs to a transient receptor potential (TRP) protein superfamily. They are voltage-
independent calcium channels that can be agonist-regulated135. In mouse erythropoietic 
progenitor cells, erythropoietin can modulate calcium influx through one of these 
channels, TRPC283,84. The function of TRPC6, however, is to inhibit calcium influx 
through TRPC285. These data suggest that balance between TRPC2 and TRPC6 is 
disrupted in Dot1L mutant progenitor cells, which may contribute to the erythropoietic 
defects in CFU assays as well as the anemia observed in vivo. It is likely that TRPC6 
deficiency results in cells that are defective in response to EPO and die. This death 
depletes erythroid progenitors and results in the anemia.  
          Because Dot1L deficiency affected Gata-2, pu.1 and Trpc6 expression, we sought 
to determine the H3K79 methylation status within each locus with the use of ChIP 
analysis. To accumulate chromatin sufficient for this analysis, we used G1E cells136, a 
proerythroblast line that express high levels of Gata-2 and low levels of pu.1 (Figure 
4.3). We found that in the actively transcribed Gata-2 locus, H3K79 mono-, di-, and tri- 
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Figure 4.3 Gata-2 and pu.1 expression in G1E cells 
We analyzed Gata-2 and pu.1 mRNA levels by RT-PCR in G1E cells. Expression of 
these genes relative to GAPDH is shown here. Gata-2 mRNA is abundant in these cells, 
suggesting its active transcription. In contrast, pu.1 mRNA is virtually undetectable in 
these cells.   
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Figure 4.4. H3K79 methylation in the Gata-2 and Pu1/Sfi1 loci.  
ChIP was performed on chromatin from the G1E cell line to assess H3K79 mono-, di-, 
and trimethylation of promoter and regulatory sites of Gata-2 and Pu1/Sfi1 loci in G1E 
cells. At the Gata-2 locus (A), which is actively transcribed, the 1S and 1G promoters 
(1S-P, 1G-P) and the first exon following each promoter (1S, 1G), as well as a regulatory 
element in intron4 (Int4) were examined. At the silenced Pu1/Sfi1 locus (B), we 
examined 2 upstream regulatory elements, 5’URE and 3’URE, as well as the promoter 
region. The data represent three independent experiments. 
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methylation are all enriched at the 1S promoter, the first exon after 1S, the 1G promoter, 
the first exon after 1G, and intron 4, which contains an important regulatory element 
(Figure 4.4 A). In the silenced pu.1 locus, we found that only mono-methylation was 
enriched in regulatory elements and in the promoter (Figure 4.4 B). We did not find di- 
and tri-methylation enrichment on these sites.  
           For the analysis of the Trpc6 locus, bone marrow and liver were used as examples 
of high TRPC6 and low TRPC6 expression, respectively137,138 (Figure 4.5). Several pairs 
of primers were designed for ChIP, that cover the entire Trpc6 locus (including the 
promoter region, the transcription start site, the middle and the end of the gene locus) 
(Figure 4.6 A). The results of ChIP showed that at the promoter region and transcription 
start site of Trpc6, H3K79 di- and tri-methylation are more enriched in bone marrow cells 
(where Trpc6 expression levels are relatively high), than in the liver cells (relatively low 
expression levels of TRPC6). In the middle of the Trpc6 locus, H3K79 di- and tri-
methylation enrichment is still higher in bone marrow cells, although not significant 
compared to liver cells. At the end of gene locus, there is nearly no difference in H3K79 
methylation between bone marrow and liver cells (Figure 4.6 B, C). These ChIP data on 
the Gata-2, pu.1 and Trpc6 loci do not directly implicate H3K79 methylation in 
regulating transcriptional activity of these genes, however they do correlate with the 
expression of these genes, and suggests a role for the histone mark in the regulation of 
their transcription. These results are in accord with previous studies showing H3K79 di- 
and tri-methylation are associated with regions of active gene expression, whereas mono-
methylation is indicative of gene regulatory elements13. 
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Figure 4.5 Trpc6 expression in bone marrow and liver.  
(A) Trpc6 expression was tested by RT-PCR in bone marrow and liver cells. Expression 
level was shown by ΔΔCt method. Trpc6 mRNA was relatively abundant in bone marrow, 
suggesting its active transcription. (B) TRPC6 protein was tested by Western Blot in bone 
marrow and liver cells. It showed that TRPC6 was expressed in bone marrow, but was 
barely detectable in liver cells.  
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Figure 4.6 H3K79 methylation in Trpc6 locus.  
ChIP was performed on chromatin from bone marrow (BM) and liver cells to assess 
H3K79 di- and tri-methylation in Trpc6 locus. (A) Several pairs of primers covering 
Trpc6 locus were designed. Their location relative to the locus was shown. H3K79 
methylation in promoter region (P1, P2), transcription start site (TSS), middle and end of 
gene locus (M, E) was analyzed. H3K79 di-methylation (B) and tri-methylation (C) were 
examined in Trpc6 locus. The data represent three independent experiments.  
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          4.2.2 Gata-2 expression is regulated by DOT1L, but this is not the mechanism by 
which DOT1L regulates hematopoiesis 
         In the gene expression study using c-kit+ yolk sac cells, one interesting finding was 
that the expression level of Gata-2 and pu.1 was differentially regulated in Dot1L KO 
samples. In Dot1L KO yolk sac progenitor cells, Gata-2 expression level reduced to 
about 50% of WT levels. At the same time, pu.1 expression increased several fold. Since 
these transcription factors play critical roles in different lineage development, my first 
hypothesis was that DOT1L is required for maintaining normal levels of Gata-2 and pu.1 
in the hematopoietic progenitor cells. When Dot1L is mutated, it will directly result in 
transcription pattern changes in Gata-2 and pu.1, which in turn causes a specific 
erythroid development defect. 
         To test the validity of this hypothesis, I first need to establish that expression 
changes of Gata-2 and pu.1 in the Dot1L KO progenitor cells is directly controlled by 
DOT1L expression. Also, I need to show that the expression changes of Gata-2 and pu.1 
are sufficient to cause erythroid defects to some extent. To this end, different cell lines 
were used as model systems in this analysis. The first step was trying to knock down 
Dot1L to determine whether Gata-2 and pu.1 expression levels were affected. The first 
cell line I tried was G1E, a genetically-engineered hematopoietic cell line. G1E cells are 
immortalized GATA-1 null erythroblasts derived from gene-targeted embryonic stem 
cells. They have been widely used in analyzing transcriptional regulation during 
erythropoiesis136. I tried both transfection of G1E cells with shRNA plasmid (pGIPz) 
targeted to mDot1L and lentiviral transduction of G1E cells, but neither of them worked. 
For instance, the percentage of cells expressing the lentiviral reporter, GFP, was 
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extremely low after two days of transfection with shRNA plasmid, even if I tried 
different protocols. In the lentiviral transduction experiments, although I obtained a 
relatively high amount of GFP+ G1E cells, Dot1L was not successfully knocked down. 
We speculate that the possible reason for this unsuccessful knock down in G1E cells is 
that DOT1L is absolutely required for the survival of this cell line. It is likely that when 
Dot1L level of certain G1E cells in a population is down regulated, critical signaling 
pathways, such as EPO signaling, are affected. Then the cells with defective DOT1L 
function will have severe defect in their growth, and will be selected against. However 
the cells in the same population with relatively normal Dot1L function will soon become 
dominant. Therefore, it is not suitable to use G1E cells as a model system for study of 
DOT1L function. 
           Another cell line, K562 cell was also used to test Dot1L knock down. 
Developmentally, K562 cells are more primitive in nature than G1E cells and behave 
more like undifferentiated early hematopoietic multi-potent progenitor cells4. It turned 
out it was much easier to do the transfection and to knock down Dot1L expression in 
K562 cells than in G1E cells. Using the pGIPz shRNA plasmid against human Dot1L, 
Dot1L transcription levels were knocked down to about 20% of the control group (Figure 
4.7 A). In order to determine whether Gata-2 and pu.1 expression is regulated DOT1L, 
real-time PCR was performed to test Gata-2 and pu.1 levels in Dot1L KO K562 cells. A 
50% reduction of Gata-2 levels was observed, a result which was quite similar in 
magnitude to our ex vivo study using yolk sac progenitor cells. However, pu.1 levels 
remained unchanged in all the experiments using Dot1L deficient K562 cells (Figure 4.7 
B, C). In order to verify this result, I repeated the experiment by transfection of K562  
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Figure 4.7 Dot1 knock down with pGIPz vector changes the expression level of  
Gata-2.  
(A). K562 cells were transfected with pGIPz vector containing sequence for shRNA 
against hDot1L or scrambled sequence as control. Dot1L level was knocked down to less 
than 20% compared to control. (B). when Dot1L was knocked down. Gata-2 level was 
reduced to about 40%. C. Dot1L KD did not change pu.1 level in K562 cells. 
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cells with pLKO.1 shRNA plasmid. As expected, Dot1L level was down regulated to 
about 30% of the control group. A 50-60% reduction of Gata-2 expression was observed 
again. However, the pu.1 level was still not affected in Dot1L knock down in these K562 
cells (Figure 4.8). These experiments indicate that only the transcription of Gata-2 is 
regulated by DOT1L directly. However the pu.1 transcription is not directly influenced 
by DOT1L level. Although previous study showed that Gata-2 deficiency induces pu.1 
expression49, we did not observe that in our study. Thus, the result in the K562 cells is 
only partially in accord with gene expression study in yolk sac progenitor cells, and my 
hypothesis is not completely supported by the results.  
             Since only Gata-2 expression seems to be reduced in Dot1L deficient cells, it is 
worthwhile to test whether Gata-2 reduction alone is able to cause hematopoietic defects. 
Gata-2 is broadly expressed in the hematopoietic system. It is expressed at particularly 
high levels in hematopoietic progenitor cells as well as in megakaryocyte lineages45. The 
function of GATA-2 has been studied using different model systems. A Gata-2 KO 
mouse showed panhematopoietic defects and embryonic lethality by E12.545. ES cells 
with deficient Gata-2 function has been used in the in vivo and in vitro differentiation 
studies and it is required for proliferation and survival of immature hematopoietic 
progenitors47. In our research, Gata-2 levels in Dot1L KO progenitor cells was reduced to 
about 50% of the wild type. This is quite similar to the expression level of Gata-2 
heterozygous hematopoietic progenitor cells. I wanted to use Gata-2+/- progenitor cells 
as model system to investigate how reduction of GATA-2 influences hematopoiesis. The 
effect of haploinsufficiency of Gata-2 on hematopoietic development is not very well 
defined. In an early study published in Nature in 1994, the hematopoietic potential of  
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Figure 4.8 Dot1 knock down with pLKO.1 vector.  
(A). K562 cells were transfected with pLKO.1 vector containing sequence for shRNA 
against hDot1L or scrambled sequence as control. Dot1L expression level was knocked 
down 70% compared to control. (B). when Dot1L was knocked down, Gata-2 level was 
reduced about 60%. C. Dot1L KD did not change pu.1 level in K562 cells. 
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Gata-2 +/- yolk sac progenitor cells was analyzed. No difference in hematopoietic 
potential between Gata-2 +/+ and Gata-2 +/- was observed. They had equal abilities to 
give rise to erythroid and myeloid colonies45. In contrast, another study analyzing GATA-
2 function in adult hematopoiesis showed opposite results. First, Gata-2+/- progenitor 
cells demonstrated decreased blood production in colony-forming assays; second, the 
stem cell compartment in the bone marrow of Gata-2+/- mice showed more significant 
changes, including a lower abundance of Lin-c-kit+Sca-1+CD34- cells and a poor 
performance in competitive transplantation assays; third, a stem cell-enriched population 
from Gata-2+/- bone marrow exhibited a greater frequency of apoptotic cells associated 
with decreased expression of the anti-apoptotic gene Bcl-xL139. Since these previous 
experiments regarding the hematopoietic potential of Gata-2+/- progenitor cells are 
apparently contradictory, I set up colony forming unit assays to directly test the 
hypothesis. My experiments showed that the Gata-2+/- yolk sac progenitor cells can give 
rise to both erythroid colonies (BFU-E), myeloid colonies (CFU-GM), and mixed 
colonies (CFU-GEMM) as efficiently as wild type control progenitors (Figure 4.9). No 
changes in the morphology of the Gata-2+/- colonies were observed. Our experiments 
were in accord with one of the previous studies45, and suggested that at least at the 
embryonic stage, a 50% reduction of Gata-2 will not generate an observable 
hematopoietic defect. All together, our results indicate that while Gata-2 expression is 
controlled by DOT1L levels, pu.1 expression is not influenced by DOT1L. Thus, the 
reduction of Gata-2 alone may not be the major reason for the hematopoietic defect in 
Dot1L deficient embryos.  
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Figure 4.9 Gata-2 +/- yolk sac progenitors did not show hematopoietic defect in CFU 
assay.   
Identical number of dissociated yolk sac cells from wild type and Gata-2 +/- E10.5 
embryos were cultured in methylcellulose growth medium supporting both erythroid and 
granulocyte-macrophage progenitors. Gata-2 +/- progenitors had the same potential as 
wild type to give rise to both erythroid and myeloid lineage colonies. 
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              The developmental program of erythropoiesis includes at least two components: 
the commitment of progenitor cells and hemoglobinizaiton. K562 cells have been used as 
a model for hemoglobin switching in previous studies140. One important feature of K562 
cells is that upon treatment with hemin or other inducing agents, K562 cells are induced 
to differentiate into hemoglobin-producing cells140,141. In our gene expression analysis of 
yolk sac progenitor cells, it was shown that Dot1L KO does not change the expression 
pattern of hemoglobin genes at the transcription level. Since I had Dot1L deficient K562 
cells available, I wanted to find out whether the lack of DOT1L affects the process of 
hemoglobin production. When Dot1L deficient K562 cells and control cells were treated 
with hemin for 36-48 hours, both group produced about 90% benzidine-positive 
hemoglobin containing cells (Figure 4.10), a result consistent with our previous benzidine 
staining test in the CFU assay (Figure 3.6). This result indicated that Dot1L deficiency 
does not affect hemoglobin generation at either the transcriptional or translational stages. 
The anemia in vivo and hematopoietic defects in vitro in the Dot1L KO samples, 
therefore, could not be attributed to defective hemoglobin production.  
            4.2.3 Trpc6 expression is affected in Dot1L deficient yolk sac progenitor cells and 
this may contribute to the erythropoietic defect 
             As discussed before, the first hypothesis about Gata-2/pu.1 transcription 
regulation by DOT1L was not supported by the studies. In this section, the second 
proposed mechanism is addressed. Since the defect is largely limited to erythroid lineage 
development, I reasoned that the failure to form large erythroid colonies in vitro and 
anemia in vivo could be due to inappropriate responses to erythroid growth stimuli. Many 
factors such as cytokines and nuclear hormones contribute to the process of  
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Figure 4.10 Hemin induction on K562 cells.  
(A-B). K562 cells transfected with pLKO.1 vector harboring scrambled sequence (A) or 
shRNA sequence against hDot1L (B) were cultured in medium containing 50 uM Hemin 
for 48 hours. Cells were stained with Benzidine to show hemoglobin expression. (C). 
Cells were counted on hemocytometer. It is shown that the percentage of hemoglobin-
containing cells in control and KD group were almost the same.  
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erythropoiesis4. For example, both interleukin-3 and Stem Cell Factor can raise the 
number of cells within BFU-E and CFU-E colonies. Insulin and Insulin-Like Growth 
Factor-I play a role at the latter stages of erythroid maturation6. Among all these factors, 
erythropoietin (EPO) plays a central role in erythropoiesis through the promotion of 
proliferation, differentiation, and survival of erythroid precursors, including CFU-E and 
BFU-E6. When EPO binds to its specific receptor on the cell surface, several signaling 
pathways are initiated71. One important function of EPO is to increase intracellular 
calcium in primary erythroid cells, which is an important signaling mechanism 
controlling the proliferation and differentiation of progenitors and precursors75,131. It has 
been shown that the calcium influx in response to EPO is mediated by transient receptor 
potential channels (TRPC)83. In erythroid cells, only two of the family members, Trpc2 
and Trpc6, are expressed and the stoichiometry of TRPC2 and TRPC6 proteins can be an 
important mechanism for regulating calcium influx in erythroid cells in response to EPO 
stimulation84,85. Interestingly, in the gene expression analysis in yolk sac progenitor cells, 
I found that at transcription level, only Trpc6 expression decreased significantly in Dot1L 
KO samples, while other TRPC members, including Trpc2, were not affected by Dot1L 
mutation. Therefore the balance between Trpc2 and Trpc6 is disrupted in Dot1L KO 
progenitor cells. Based on the results from other research groups and my own findings, 
my second hypothesis is that Dot1L deficiency results in down regulation of Trpc6. The 
change of stoichiometry of TRPC6 and TRPC2 in turn, results in abnormal calcium 
influx in response to EPO during erythropoiesis, which leads to a relatively specific 
erythropoietic defect.    
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           In the previous section, Trpc6 expression at the transcriptional level was shown to 
be decreased significantly in Dot1L KO yolk sac progenitor cells. It is necessary to find 
out whether Trpc6 expression at the translational level was also affected by Dot1L 
mutation. Since the protein amount from the progenitor cells of a single yolk sac was 
very little, c-kit+ yolk sac cells of the same genotypes were pooled together to perform 
Western Blot (Figure 4.11). Due to low protein concentration, the signal on the Western 
Blots was not very strong. By doing quantification using ImageJ software, we determined 
that TRPC6 levels in Dot1L KO progenitors was reduced by about 40% compared to the 
WT group. This result was consistent with previous RT-PCR results and supported my 
hypothesis, indicating that Dot1L deficiency indeed changes Trpc6 expression. 
          Next, it was important to find out whether calcium influx in response to EPO was 
changed in Dot1L KO hematopoietic progenitors due to the reduction of Trpc6 levels. 
Calcium is a ubiquitous intracellular signal responsible for controlling numerous cellular 
processes. The extracellular concentrations of calcium in most cells are generally quite 
high, 3-4mM. However, the concentrations inside the cell are tightly controlled and 
usually kept at or below 100nM. Different types of stimuli will generate the calcium 
mobilizing signals, which increase intracellular calcium level to around 1000nM. The 
increased calcium level will create a wide range of signals that play critical roles in 
biological processes as diverse as fertilization, proliferation, development, contraction 
and secretion79. Importantly, though calcium signaling is important and necessary, it is 
also potentially toxic to the cells. Intracellular free calcium is a key element responsible 
for a number of calcium-dependent apoptosis pathways78. Therefore, a balance of 
calcium and homeostasis is important for both survival as well as normal responsiveness  
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Figure 4.11 Dot1L deficiency results in TRPC6 protein level reduction in c-kit+ yolk 
sac cells.  
（A) c-kit+ yolk sac cells from 6 individual Dot1L KO embryos and 6 individual wild 
type embryos were pooled together and protein was extracted for Western blot. (B) 
Western blot image was analyzed by ImageJ software. Signal intensity of Dot1L KO 
group decreased 40% compared with wild type group.  
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to extracellular signals. Intracellular calcium is measured with the use of different kind of 
calcium ion probes, such as Fura-2 or Calcium Green-1. Fura-2 was used in my 
experiments. It is a ratiometric indicator that exhibits a shift in its absorption or excitation 
peak from 380nm to 340nm upon binding calcium84. Whole yolk sacs were dissociated 
into single cells and were fixed to the bottom of the culture dishes. The yolk sac cells 
were then stained with Fura-2. At the beginning of the experiment, cells were treated with 
EPO at 10 U/ml. The calcium signal in individual cell was recorded on a fluorescent 
microscope for 20 minutes (Figure 4.12). In each yolk sac, the signals of about 30 
individual cells were recorded and analyzed. Among these cells, I usually could observe 
3 to 4 cells in which the calcium signal changed. The rest of the cells in the group had no 
response to EPO addition and were not taken into account. This makes sense, because 
hematopoietic progenitor cells (C-kit+ enriched) constitute only about 10% of the whole 
yolk sac cells, (as shown in our flow cytometry analysis, Figure 3.8) and they make up 
the population that is supposed to react to EPO treatment. From figure 4.12, it shows that 
the response of wild type cells to EPO was relatively slow. After about 5 minutes, the 
calcium signal started to go up gradually. After about 17 minutes, a plateau was formed 
on the curve, meaning the intracellular calcium concentration stopped going up. In sharp 
contrast, the Dot1L KO cells responded promptly and the calcium signal went up right 
after EPO treatment. The slope of the curve was much steeper than that of the wild type, 
indicating a much faster calcium influx in Dot1L KO cells. Even after 17 minutes, the 
curve did not level off. Thus the final calcium signal in Dot1L KO cells after 20 minutes 
of EPO treatment was much higher than WT cells. This figure is a representative of three 
experiments using three individual litters. The curve in the figure is not the signal of one  
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Figure 4.12 Intracellular calcium change in yolk sac cells upon EPO treatment. 
E10.5 Dot1L KO and WT yolk sac cells were stained with calcium imaging dye Fura-2 
and treated with EPO (10U/ml). Calcium signal in individual cell was recorded by 
fluorescent microscope for 20 minutes. The curve represented the composite result of 
multiple cells (KO n=5; WT n=6).  
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cell, but is the composite curve of several cells from three or more individual yolk sacs of 
the same genotype. The trend of the curves looked similar in all experiments. In 
summary, the results from the calcium imaging assays were consistent with previous 
studies about the function of TRPC2 and TRPC685. Since high intracellular calcium is 
able to trigger calcium-mediated apoptosis, this result was in accord with our apoptotic 
analysis with yolk sac cells undergoing erythropoiesis. Also the result supported my 
second hypothesis, indicating that Dot1L deficiency results in abnormal calcium influx in 
response to EPO; this abnormal response may contribute to the observed erythropoietic 
defect.  
           Next, it would be important to test whether the abnormal calcium influx is really 
the factor for erythropoietic defect in Dot1L KO progenitor cells. I reason that if the high 
calcium concentration does play a critical role in Dot1L KO progenitor cells, the 
hematopoietic defects would be rescued if the abnormally high calcium level is decreased 
by some means. One of the possible ways is to use the calcium specific chelator to reduce 
intracellular calcium142. Different concentration of calcium chelator in the growth 
medium would be able to reduce intracellular calcium levels of Dot1L KO progenitor 
cells to different extents. If a wide range of concentrations for the chelator in the medium 
is attempted, it is possible that certain concentration could be identified that could reduce 
intracellular calcium of Dot1L KO progenitor cells to a level comparable to WT cells, in 
response to EPO treatment. The erythropoietic defect should be rescued at least to some 
extent if the calcium concentration is really critical.  
           Our experiment and studies from others showed that during the first minutes of 
EPO stimulation, the intracellular calcium level does not increase extensively. These 
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observations suggested that the calcium level increase is not due to intracellular calcium 
release. Using HEK 293T cells as model system, it has been shown that extracellular free 
calcium is the source of calcium increase in response to EPO74. EGTA (ethylene glycol 
tetraacetic acid) has been widely used in many calcium influx analyses74,143. EGTA is a 
chelating agent with higher affinity for calcium than magnesium and it usually exerts its 
function outside the cells. The divalent calcium ion can be bound by the multiple anionic 
carboxyl groups of EGTA and the intracellular calcium level can be finally suppressed144. 
Based on previous research, 10mM EGTA is high enough to inhibit calcium influx143. 
The strategy of this experiment was quite straightforward. It was just like a previous CFU 
assay, except that different amounts of EGTA were added to M3434 medium. I started 
with 12mM EGTA in the medium, which is supposed to inhibit calcium influx 
completely, and tested various concentrations all the way down to 1 mM. In each 
experiment, M3434 without EGTA was used in the control plate. The experiments have 
been attempted in 8 litters including 13 Dot1L KO embryos. Although extensive EGTA 
concentrations were tested, no rescue of the erythropoietic defect in Dot1L KO progenitor 
cells was observed at any EGTA concentration. When EGTA is higher than 1.3mM, the 
colony growth was severely inhibited. There were no erythroid colonies at all. A few 
small colonies that appeared to be small CFU-GM could be observed on the culture dish. 
But their colony size was much smaller than CFU-GM in the control group. All 
concentrations higher than 1.3mM seem to have the similar inhibitory effect. When 
EGTA was lower than 1.2 mM, it lost its inhibitory effect completely. The colony 
numbers per dish and colony size were comparable to the control group (Figure 4.13). It 
appears that EGTA’s effect on calcium influx in yolk sac progenitor cells is quite abrupt:  
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Figure 4.13 Erythropoietic defect of Dot1L progenitor cells can not be rescued by 
adding EGTA to growth medium. (A). Dot1L KO yolk sac cells were grown in medium 
containing various concentration of EGTA. When EGTA concentration was higher than 
1.3mM (from 1.3mM to 20mM), erythroid colonies were completely inhibited and no 
recovery was observed. Reduced number of myeloid-like colonies were found. When 
EGTA concentration was lower than 1.2mM, it lost its potency completely, yielding 
comparable erythroid colonies and myeloid colonies with control group. . (B-C). 
Representative pictures of colonies derived from culture with 1.3mM (B) or higher 
concentration (C) of EGTA. (D-E). Representative pictures of colonies derived from 
culture with EGTA lower than 1.2mM. Erythroid colony (D) and myeloid colony (E) are 
shown here. (F-G). Typical erythroid colony (F) and myeloid colony (G) derived from 
Dot1L KO yolk sac cells in M3434 medium without EGTA. (Note: scale bar represents 
100um)  
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either completely inhibitory or completely incompetent. Therefore, EGTA was not a 
suitable reagent for the rescue experiment of Dot1L KO yolk sac progenitor cells.    
           4.3 Discussion 
           Transcriptional regulation plays a critical role in hematopoietic progenitor cell 
differentiation and proliferation. Dysregulation of transcriptional mechanisms usually 
results in anemia and specific leukemias5. Since DOT1L has been proposed to play a 
potential role in gene expression regulation92, I initiated the mechanistic studies of 
DOT1L in hematopoiesis by comparing the expression level of certain critical genes in 
Dot1L KO progenitor cells with wild type progenitor cells. Among more than twenty 
genes analyzed, only the expression levels of five genes were significantly affected by 
Dot1L mutation: Gata-2 and Trpc6, which were reduced; and pu.1, scf, and Trap220, 
which were all increased.  
            Although H3K79 methylation is observed universally throughout the genome, 
Dot1L mutation only results in transcription change in a subset of genes. This interesting 
phenomenon has been reported by several research groups using different model 
systems13,108. All of the observations led to a hypothesis that only a subset of 
developmentally regulated genes requires DOT1L for their normal expression. Our 
results were consistent with these previous studies, indicating that during embryonic 
hematopoiesis, only certain important genes are affected by Dot1L mutation. We predict 
that the expression pattern changes of these important genes would contribute to the 
erythropoietic defect. 
             In my studies, the research has focused on three genes: Gata-2, pu.1, and Trpc6. 
The reason for this preference is that the expression pattern change of these three genes is 
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closely associated with the erythropoietic defect phenotype. GATA family factor and 
PU.1 are lineage-specific transcription factors and play critical role in lineage 
commitment decisions53. Gata-2 is expressed in hematopoietic stem and progenitor cells 
and is important for erythroid lineage development. In contrast, pu.1 is critical for 
myeloid lineage development and it is essential to suppress pu.1 function for normal 
erythroid cell development50,53,54. Trpc6 belongs to a protein family of voltage-
independent calcium channel and is expressed specifically in erythroid progenitor cells. It 
is supposed to play an essential role in calcium regulation in response to EPO during 
erythropoiesis. Dysregulation of calcium in the progenitor cells will lead to either 
apoptosis or failure to grow74,85.  
             Although the function of SCF and TRAP220 in hematopoiesis has been well 
recognized, the expression pattern change of these genes is not likely to result in defects 
observed in Dot1L KO hematopoietic progenitor cells. SCF is critical for erythroid 
lineage development, since mutation in scf or its receptor c-Kit leads to significant 
reduction of fetal liver CFU-E progenitors and severe anemia4. But in our experiments, 
scf expression levels went up in Dot1L KO progenitor cells, not quite consistent with the 
anemia phenotype. TRAP220 deficient progenitor cells also have defect specific in the 
erythroid, but not the myeloid lineage. More importantly, TRAP220 is also very 
important in globin gene expression. -globin expression is abrogated in Trap220 mutant 
embryos5. In our experiments, however, an increase in Trap220 expression was observed 
in Dot1L KO progenitor cells, and globin gene expression pattern was not affected. All of 
the results implied that Trap220 expression change in Dot1L KO progenitor cells may not 
be responsible for the erythroid defect. 
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               GATA-2 and PU.1 are transcription factors that play critical roles in lineage 
specific development. My first hypothesis was that DOT1L is required for maintaining 
the normal level of Gata-2 and pu.1 in the hematopoietic progenitor cells. When Dot1L is 
mutated, it will directly result in transcription pattern change of Gata-2 and pu.1, which 
in turn causes specific erythroid development defect. This hypothesis was not supported 
by the experimental results. I observed Gata-2 and pu.1 differential regulation in Dot1L 
KO progenitor cells and wanted to test whether these two genes were directly regulated 
by DOT1L in an in vitro model. In K562 cells, only Gata-2 transcription was regulated 
by DOT1L. Pu.1 levels were not affected. This is not consistent with our observation in 
yolk sac progenitor cells. A possible explanation for the gene expression change and 
erythropoietic defect in Dot1L KO progenitors is that Gata-2 is the only transcriptional 
regulation target of DOT1L. The higher level of pu.1 in Dot1L KO yolk sac cells is not 
due to direct transcriptional regulation, but rather is an accumulated result of 
developmental defect during hematopoiesis. For instance, an erythroid-lineage specific 
defect will result in predominance of myeloid progenitors in the whole progenitor 
population, which could change the overall gene expression pattern of yolk sac 
progenitors.  
             Since only Gata-2 expression seems to be regulated by DOT1L, I analyzed 
whether Gata-2 reduction alone (haploinsufficiency) is able to cause hematopoietic 
defects. The effect of Gata-2 haploinsufficiency on hematopoiesis has been tested in yolk 
sacs at both the embryonic stage and bone marrow in adult stage45,139. My result was 
consistent with the study carried out in yolk sac cells, showing that a 50% reduction of 
Gata-2 alone would not cause observable hematopoietic defects at the embryonic stage. 
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This result was quite distinct from the study in bone marrow at the adult stage. It is 
possible that the function of GATA-2 is different at various developmental stages. At the 
embryonic stage, 50% expression of Gata-2 is sufficient to maintain normal 
hematopoietic development. But at the adult stage, GATA-2 becomes more important 
and the expression of Gata-2 from both alleles is required for maintaining adult 
hematopoietic stem cells.  
           Another important finding in my gene expression studies in yolk sac cells was that 
Trpc6 expression was reduced dramatically in Dot1L KO progenitors. My second 
hypothesis was that Dot1L deficiency resulted in down regulation of Trpc6. The change 
of stoichiometry of TRPC6 and TRPC2 in turn results in abnormal calcium influx in 
response to EPO during erythropoiesis, which leads to a specific erythropoietic defect. 
This hypothesis was supported by some of my experiments. First, Trpc6 expression is 
closely associated with DOT1L level. At both the transcriptional and translational level, 
Dot1L KO results in Trpc6 reduction in the c-kit+ yolk sac progenitor cells, suggesting 
DOT1L and H3K79 methylation play a role in Trpc6 expression regulation. Second, 
calcium influx in response to EPO was abnormal in Dot1L KO yolk sac cells, and this 
may potentially contribute to the erythroid lineage defect. However, when I tried to 
rescue the erythroid defect by changing intracellular calcium level in Dot1L KO yolk sac 
cells, no rescue was observed by using EGTA, the calcium chelating agent. The effect of 
EGTA was either a complete inhibition of erythroid colony formation or no function at 
all in Dot1L KO yolk sac cells.  
             In a previous study, 5mM EGTA was used to inhibit erythroid colony formation, 
which was higher than I found80. The difference could be due to different methods and 
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medium used in colony forming assay. In that study, which was performed 30 years ago, 
erythroid colonies were grown employing the plasma clot technique80. In my experiment, 
MethoCult® GF M3434 from StemCell Technology was used. It is optimized for the 
detection and quantification of mouse hematopoietic progenitors in various tissues. The 
inhibition of erythroid colony formation was largely due to change of intracellular 
calcium concentration by EGTA. EGTA is a chelating agent with a much higher affinity 
for calcium than for magnesium ions. The specificity was shown by the fact that 
inhibition of erythroid colony formation by EGTA could be rescued by calcium, but not 
by magnesium, zinc or other ions80.    
          An interesting phenomenon in EGTA chelating experiment was that when 
erythroid colonies were completely inhibited by EGTA higher than 1.3mM, myeloid 
colonies could still be observed, although the colonies number and size of these myeloid 
colonies were significantly reduced compared to the control group. This indicates that 
erythroid progenitor cells are more sensitive to intracellular calcium concentration 
changes than myeloid progenitors. This result was consistent with previous data that the 
regulation of intracellular calcium by EPO was especially critical for the proliferation and 
differentiation of erythroid progenitors75,131. Another thing that should be pointed out is 
that although small myeloid colonies could be observed in medium containing higher 
concentrations of EGTA, they were only identified by their morphology. Their identity 
could be further confirmed by myeloid specific antibody staining, such as Mac-1 and Gr-
1.   
           As I discussed previously, dissociated whole yolk cells were used in the calcium 
imaging experiment. The yolk sac is a bilayer structure, consisting of mesoderm-derived 
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and endoderm-derived cell layers1,18. In my experiments, the intracellular calcium of only 
3-4 cells was changed upon EPO treatment among 30 cells recorded. This is consistent 
with our previous result that hematopoietic progenitor cells (represented by c-kit+ cells) 
only account for 6-10% of the whole population. The quality of the experiment would 
have been improved if enriched hematopoietic progenitor cells in the yolk sac were used. 
           The erythropoietic defects could not be rescued using EGTA under current 
experimental conditions. However, the second hypothesis is still supported by some 
experimental results and looks promising. Other agent should be applied in future studies, 
such as BAPTA-AM, which exerts its function in a different way from EGTA145. 
BAPTA-AM has been extensively used as an intracellular calcium-specific chelator. It 
does not bind calcium until it penetrates the cells and is hydrolyzed by cytoplasmic 
esterases into its active form. Therefore, it will selectively buffer intracellular calcium 
levels without affecting extracellular concentrations145. 
 
 
 
 
 
 
 
 
 
 
	 124
Chapter 5 
General Discussions 
               A critical role for the DOT1 Histone H3, Lysine 79 (H3K79) methyltransferase 
in telomeric silencing was first described in Saccharomyces cerevisiae97. In the 
subsequent ten years, a vast array of functions have been attributed to the protein, 
including roles in transcriptional regulation, DNA repair, cell cycle regulation, and 
embryonic development, in a variety of different model systems, including the fruit fly, 
various mammalian cell lines, and in mice10-13,108. In this dissertation, I focus on the role 
of the methyltransferase in mouse embryonic hematopoiesis. Precise regulation of 
H3K79 methylation is absolutely required for mouse embryonic development and 
deletion of Dot1L results in embryonic lethality at around mid-gestation7. In these initial 
studies, defective vascular development was reported, but no clear reason for the lethality 
was described12. In order to perform a more in depth mechanistic analysis of Dot1L’s 
function during this period of embryonic development, with the goal of obtaining greater 
insight into the potential cause of the lethality, a gene-trap based Dot1L KO mouse line 
was established in our laboratory. In this mouse, we also were able to observe the 
reported lethality at approximately the same time during development. In addition, we 
observed a severe anemia in the Dot1L KO embryos. We performed colony forming unit 
(CFU) assays on yolk sac cells at around the time of the observed anemia and lethality 
(E10.5). These analyses confirmed that, indeed, there was severely deficient 
hematopoiesis (specifically, erythropoiesis) in the Dot1L-null yolk sac progenitors at this 
time7. In terms of mechanism, Dot1L deficiency blocked cell cycle progression and 
promoted apoptosis of these hematopoietic progenitor cells (Chapter 3). To investigate 
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the molecular mechanism, regulation of the expression of genes that are critical for 
hematopoiesis by DOT1L was analyzed. We initially observed that Gata-2 expression 
appeared to be regulated by DOT1L. As a result of further analysis, we concluded that a 
simple reduction of Gata-2 in the progenitors would not lead to the hematopoietic defects 
that we described. We then focused on the failure of the progenitors to thrive, and/or 
proliferation in response to EPO stimulation. Gene expression analysis revealed that 
Trpc6, a channel that plays a critical role in EPO mediated calcium influx, was 
significantly down regulated in Dot1L KO progenitors. Associated with this down-
regulation was the observation of an abnormal intracellular calcium response in Dot1L 
KO progenitors after EPO treatment (Chapter 4). Taken together, the data support our 
conclusion that abnormal EPO responses in erythroid progenitor cells lead to excessive 
increases in calcium flux. This excessive increase leads to a failure of the progenitor cells 
to thrive and proliferate, and ultimately induces the cells to initiate an apoptosis program. 
The induced death of these cells is consistent with all of our cellular and molecular data, 
including the defective cell cycle progression and increased apoptosis of the erythroid 
progenitors, the reduced colony formation, and the embryonic anemia. The data help to 
broaden our understanding of the cellular and biological functions of Dot1L. Furthermore, 
this in depth molecular analysis provides us more insight into the intricate regulation of 
embryonic hematopoiesis.  
            5.1 The diverse functions of DOT1 
            The unique properties of DOT1 are reflected in two aspects. First, unlike most 
histone lysine methyltransferases, it does not contain the conserved SET domain, which 
is required for enzymatic activity and has been considered a signature structure for this 
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class of enzymes. Instead, its catalytic domain contains conserved sequence motifs 
similar to class I methyltransferases such as DNA methyltransferase (DNMT) and the 
protein arginine methyltransferase PRMT189,127. Second, its substrate, H3K79 is located 
at the loop1 region within the globular domain of histone H3, which is quite different 
from most other important histone marks on tails of histones H3 or H491. In addition, 
DOT1 in yeast and its homolog in other species is the only enzyme responsible for 
H3K79 methylation7,12. Therefore its function is considered non-redundant and 
indispensible for biological process.  
           Dot1 was first identified in a genetic screen for genes whose overexpression 
disrupts telomeric silencing97. Interestingly, both overexpression and deletion, as well as 
mutation on H3K79 destroy silencing at telomeres10. It has been proposed that the 
balance between Sir proteins and the level of H3K79 methylation is important for 
regulating heterochromatin formation at telomeres, since the recruitment and binding of 
Sir proteins are critical for the establishment of telomere and telomere-proximal DNA 
silencing10. It needs to be noted that recent studies have challenged this established model 
and implied that DOT1 may not as critical in heterochromatin formation as previously 
thought146,147.   
              Besides its function in telomere silencing, Dot1 and H3K79 methylation are also 
involved in transcriptional regulation. In yeast, 90% of the genome is enriched with 
H3K79 methylation and is actively transcribed at the same time. Meanwhile, the other 10% 
of the genome lacks H3K79 methylation, but is enriched with Sir proteins10,103. In 
Drosophila, chromatin immunoprecipitation coupled with gene expression microarray 
(ChIP-chip) revealed a positive correlation between H3K79 di-methylation and active 
	 127
gene transcription105. Using a mammalian cell line, it was shown that H3K79 methylation 
marks are localized within the body of actively transcribed genes, and H3K79 
methylation levels correspond to transcriptional activity13. Data from this dissertation are 
generally consistent with this view. In G1E cells, H3K79 di- and tri-methylation were 
found enriched in important regulatory elements of the actively transcribed Gata-2 locus. 
In the silenced pu.1 locus, no H3K79 di- and tri-methylation enrichment was observed at 
the promoter region, nor in the upstream regulatory elements7. In the Trpc6 locus of bone 
marrow cells, where it is actively expressed, H3K79 di- and tr-methylation were much 
higher than in the Trpc6 locus in liver cells expressing very low levels of Trpc6.  
  Studies using mammalian cell lines and ES cells revealed an interesting 
phenomenon that the loss of Dot1L results in transcriptional changes in only a subset of 
genes, despite the fact that H3K79 methylation is a universal modification13,108. My 
results are consistent with these observations. Among more than twenty genes analyzed, 
only a few of them are affected by Dot1L deficiency7. All of these observations lead to a 
hypothesis that only a subset of developmentally regulated mammalian genes requires 
DOT1L for their normal expression. One possible explanation for this phenomenon is 
that DOT1 might be functionally antagonistic to epigenetic silencing. Certain mammalian 
gene-silencing complexes (e.g. HP1 or Polycomb proteins) and the repressive histone 
mark H3K9 are found to exist over proximal transcribed regions of certain genes. The 
presence of these silencing proteins constitutes the requirement of Dot1L function. The 
location of H3K79 on the top and bottom of surfaces of the nucleosome suggests that its 
methylation could change the interaction between the nucleosome and other proteins, 
including silencing proteins. H3K79 di- and tri-methylation enriched within proximal 
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transcribed regions of a gene locus may change the critical protein-protein interactions 
required for a repressive chromatin conformation, therefore enabling promoter escape by 
elongation complexes under such conditions13. Another possible explanation is derived 
from purification of a number of transcriptional elongation complexes. Since genome-
wide localization studies implied a potential role for H3K79 methylation in transcription 
elongation, several elongation complexes have been analyzed to ascertain the 
involvement of DOT1L14,148. It turns out that DOT1L is indeed included in some 
complexes, but not in others. It is likely that multiple transcriptional elongation 
complexes may exist, and DOT1L only associates with a subset of these complexes. 
When Dot1L is absent, expression of only those genes whose transcription requires a 
DOT1L-containing elongation complex will be affected92.These are some possible 
explanations that have not been fully tested. Furthermore, another purified DOT1L-
containing complex includes both transcription activators (ENL) and repressors 
(SIRT1)149. It seems that DOT1L could mediate both transcriptional activation and 
repression through facilitating and integrating the opposing forces of positive and 
negative factors. Therefore, the mechanism of transcription regulation by DOT1 still 
remains a puzzle. In most cases, it seems that DOT1 plays its role in a locus-specific 
manner. 
            DOT1L has been implicated in cell cycle progression in ES cells as well as 
primary erythroid progenitor cells. In ES cells, the proliferation and pluripotency were 
not affected upon Dot1L deficiency, but severe proliferation defects were observed 
during differentiation, resulting in G2/M phase accumulation108. In contrast to that 
observed in ES cells, Dot1L KO in erythroid progenitor cells in our experiments showed 
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an accumulation at the G0/G1 phase7. This suggests that the cell cycle effects of DOT1L 
might be cell type-specific, or ligand-selective. The reason for this specificity in cell 
cycle regulation by DOT1L deserves further studies in the future.  
            Dot1L plays an important role in embryonic development. A Dot1L KO mouse 
line established by another group showed lethality by E10.5 during organogenesis of the 
cardiovascular system12. Our lab generated a gene-trap based Dot1L KO mouse line. We 
also observed embryonic lethality by E13.5, with severe anemia in Dot1L KO embryos7. 
In spite of this discrepancy (potentially due to the different methods used to generate the 
different mutant embryos), both results indicate that DOT1L is absolutely required for 
mouse embryonic development.  
            Dot1L KO embryos demonstrate cardiovascular defects, indicating that it plays a 
significant role in development of the cardiovascular system12. Interestingly, this may not 
be the major reason for the embryonic lethality in these mice. A cardiac-specific Dot1L 
KO mouse line showed that Dot1L deficiency in cardiomyocytes does not cause 
embryonic lethality114. In our experiments, severe anemia was observed and confirmed in 
Dot1L KO embryos. Since defective hematopoietic development is a common cause of 
embryonic death during mid gestation, we estimate that the hematopoietic defect upon 
Dot1L deficiency would be the major contributor to embryonic lethality. Future studies 
with hematopoietic-specific Dot1L KO model are required to confirm our prediction.   
              Besides the important role in normal embryonic and adult hematopoiesis, 
transcriptional activation by DOT1L mediated H3K79 methylation is also exploited in 
leukemogenesis. Translocation of MLL gene in leukemia leads to the interaction between 
the translocation partners and DOT1L. Mistargeting of DOT1L to the gene targets of 
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MLL fusion proteins results in aberrant hypermethylation of H3K79 and constitutive 
transcriptional activation of these genes. This, in turn, is thought to result in leukemic 
transformation115,118,119. Dot1L has been proposed to be a target for leukemia treatment. 
Although we need to bear in mind that DOT1L plays a role in normal hematopoiesis, it 
does not exclude the possibility of using small molecule inhibitors that target DOT1L, 
since normal hematopoietic stem/progenitors and leukemic cells may have different 
sensitivity to these inhibitors92,150.  
          5.2 Mechanistic studies of Dot1L in hematopoiesis 
          After the hematopoietic defect in Dot1L KO progenitor cells was identified, I have 
been trying to determine the mechanism. Since transcriptional regulation of important 
factors in hematopoiesis plays a critical role in proliferation and differentiation of 
progenitor and precursor cells, and DOT1L has been shown to be a potential regulator of 
transcription13, I started the mechanistic study by analyzing the transcription pattern 
changes of genes that are important in hematopoiesis.  
            The expression pattern changes in Gata-2 and pu.1 in Dot1L KO progenitors drew 
our attention at first. There is a 50% reduction of Gata-2 and several fold increase of pu.1 
at the transcriptional level in c-kit+ yolk sac cells when Dot1L is knocked out. GATA-2, 
GATA-1, and PU.1 are lineage-specific transcription factors expressed in multipotential 
progenitors5. Activation of specific transcription factors facilitates lineage commitment of 
progenitor cells down a particular differentiation pathway. GATA family proteins are 
essential for erythroid lineage development, while PU.1 is required for development of 
the myeloid lineage. The antagonistic relationship between GATA family proteins and 
PU.1 was elucidated many years ago53. A facet of that regulation is at the stem cell or 
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multipotential progenitor stage, where GATA-2 is expressed and inhibits PU.1 function 
by preventing its binding with its coactivator C-Jun. When progenitor cells develop along 
the erythroid pathway, GATA-2 is replaced by GATA-1, and PU.1 function is still 
inhibited by GATA-1. When progenitor cells develop into the myeloid lineage, both 
GATA-2 and GATA-1 are repressed and PU.1’s function becomes dominant38,49,54,151. 
The Gata-2/pu.1 expression pattern in Dot1L KO progenitors is in accord with the 
erythropoietic defect observed in CFU assay7. Therefore, my first hypothesis proposed 
that Dot1L mutation results in transcription pattern change of Gata-2 and pu.1, which in 
turn causes specific erythroid development defect. However, it was not fully supported by 
subsequent experiments. First, only Gata-2’s expression is directly regulated by DOT1L. 
The expression of pu.1 is not affected by Dot1L deficiency, as shown in K562 cells. 
Second, the reduction of Gata-2 itself will not cause observable hematopoietic defect, at 
least in embryonic stage. It is possible that the increase of pu.1 expression observed in 
yolk sac cells is a reflection of accumulated developmental defect, rather than the direct 
transcription regulation by DOT1L. The c-kit+ progenitor cells are not a homogeneous 
population. They consist of multipotential progenitors as well as lineage committed 
progenitors such as common myeloid progenitors, granulocyte-monocyte progenitors and 
megakaryocyte-erythrocyte progenitors152. The multipotential progenitors “prime” 
several different lineage-specific program of gene activity (e.g. transcription factors, 
cytokine receptors) at relatively low level. Once the multipotential progenitors are 
committed to one particular lineage, upregulation of genes associated with the 
appropriate lineage and downregulation of genes with other lineages occur49,153. We 
speculate that the altered expression patterns of GATA2 and PU.1 are the result, rather 
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than the cause of the defective progenitor function. Increased apoptosis of cells 
responding to EPO would result in a pool of progenitors that lack erythroid and are 
enriched in a myeloid-generating population. These myeloid progenitor cells would have 
increased PU.1 expression and decreased GATA2, as has been reported50,52. 
              An important reason for the specific erythropoietic defect is the inappropriate 
response to erythroid growth stimuli. EPO is considered the master regulator of 
erythropoiesis and one of its important functions is to induce calcium influx in the 
progenitor cells through TRPC proteins4,135. In mouse, only Trpc2 and Trpc6 are 
expressed in the erythropoietic lineage. The stoichiometry of expression of Trpc2 and 
Trpc6 is an important mechanism for hematopoietic cells to regulate calcium influx in 
response to EPO stimulation. The ratio of TRPC2/TRPC6 expression on the cell 
membrane is thought to be required to regulate a normal EPO response. Changes in the 
expression of either of these two factors will affect this ratio and result in abnormal 
calcium influx and potentially, in defective hematopoiesis74,84,85,135. Gene expression 
analysis in progenitor cells revealed a significant reduction of Trpc6 in the absence of 
Dot1L. Thus, my second hypothesis was that Dot1L deficiency results in down regulation 
of Trpc6, and leads to a change in the stoichiometric ratio of TRPC6:TRPC2, which in 
turn, results in abnormal calcium influx in response to EPO during erythropoiesis. 
Generally, this hypothesis has been supported by the data. The expression of Trpc6 is 
closely correlated with H3K79 methylation status in the locus. In Dot1L KO yolk sac 
cells, Trpc6 expression is dramatically decreased at both the mRNA and protein levels. In 
bone marrow cells, where Trpc6 is highly expressed, the Trpc6 locus is enriched with 
H3K79 di- and tri-methylation. In liver cells, where Trpc6 is silenced, the H3K79 
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methylation level is much lower. This strong correlation implies that DOT1L or H3K79 
methylation may play a role in the regulation of Trpc6 expression. Moreover, a calcium 
imaging assay showed that EPO treatment elicits a significantly increased calcium influx 
in Dot1L KO yolk sac cells. It would have been nice if the erythropoietic defect in Dot1L 
KO could be rescued by EGTA treatment. We speculate that this was due to the abrupt 
chelating effect of EGTA rendered by its specific chemical properties, resulting in 
quantal changes in Calcium chelation142. Other modes of Calcium chelation could be 
tried in future experiments.   
            5.3 Future directions 
            Dot1L has been shown to play a critical role in both embryonic and adult 
hematopoiesis by our group and others. But the molecular mechanism(s) of Dot1L 
function during normal hematopoiesis has not been fully investigated. Using a 
conditional Dot1L KO model, two other groups demonstrated Dot1L’s role in 
maintaining normal adult hematopoiesis15,115. Unfortunately, they did not carry out any 
mechanistic studies or propose a hypothesis about Dot1L function in hematopoiesis. In 
my study, two hypotheses have been proposed and one of them is largely supported by 
the data. However, to fully prove the hypothesis and more thoroughly investigate Dot1L 
function in hematopoiesis, more extensive experiments need to be done. In the following 
part, some of the important directions will be discussed.  
            In my hypothesis, Trpc6 is the major target gene affected by Dot1L KO. Down 
regulation of Trpc6 is considered the major cause of abnormal calcium influx and defect 
in erythropoiesis. It is necessary to perform a Trpc6 overexpression experiment in Dot1L 
deficient progenitor cells. If Trpc6 is indeed critical in this process, restoration of Trpc6 
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to relatively normal levels in Dot1L deficient progenitor cells should rescue the 
erythropoietic defect, at least to some extent. In this experiment, analysis of c-kit+ yolk 
sac cells would not be the ideal system due to the limitations in cell numbers in each yolk 
sac. In addition, it has been recognized that the nature of yolk sac progenitor is transient, 
and thus, not convenient to do genetic manipulation154. In contrast, ES cell differentiation 
approaches are very useful in studying erythropoiesis. Established protocols to induce ES 
cell into the hematopoietic lineages are available. Hematopoietic differentiation from ES 
cells proceeds in a synchronous manner, which facilitates cellular and molecular studies. 
Genetically modified ES cells can be used to study the effects of the genetic modification 
on hematopoietic differentiation4. This would be especially helpful in our studies, since 
Dot1L KO is embryonically lethal. Our laboratory is making a conditional Dot1L KO 
mouse line. In this mouse line, an important exon in Dot1L locus, required for 
methyltransferase activity12, is flanked by LoxP. The mouse also expresses Cre-estrogen 
receptor, which will produce Cre recombinase upon Tamoxifen. When the cells from the 
mouse line are treated with Tamoxifen, Dot1L will be functionally deleted. Embryonic 
fibroblast cells (MEF) can be easily derived from embryos from this mouse line to 
produce induced pluripotent stem cells (iPS cells). With the iPS cells, we can do many 
kinds of analyses, including induced knockout of Dot1L, hematopoietic differentiation of 
Dot1L conditional KO iPS cells, gene expression studies, as well as overexpression of 
Trpc6 in Dot1L KO cells. By doing these experiments, the function of Trpc6 in the 
regulation of hematopoiesis by Dot1L will be confirmed, and my hypothesis will be 
further supported.  
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            As discussed earlier, the transcriptional activation of DOT1L-mediated H3K79 
methylation also plays an important role in leukemogenesis. Although we need to fully 
understand DOT1L’s function in normal hematopoiesis, it does not rule out the feasibility 
of using DOT1L as a target in leukemia treatment. Recently, several groups have 
reported the development of potent DOT1L-specific inhibitors150,155. Some of the 
inhibitors show highly selective inhibition of DOT1L methyltransferase activity, and 
exhibit only weak or no activities against other histone lysine or arginine 
methyltransferases. The high selectivity was confirmed by X-ray crystal structure of a 
DOT1L-inhibitor complex155. It is possible that normal hematopoietic stem 
cells/progenitor cells and leukemic cells may have different sensitivities to DOT1L 
inhibitors. Therefore in the future, it would be necessary to compare the sensitivity of 
normal hematopoietic stem/progenitor cells with leukemic cells to various potent DOT1L 
inhibitors. By doing this, we can determine which type of inhibitor has more selectivity 
against leukemic cells and what dosage of the inhibitors is specifically inhibitory in 
leukemic cells, but is tolerable in normal cells. 
          One more concept that we need to keep in mind is that H3K79 methylation is a 
universal histone mark. Accordingly, Dot1L expression is ubiquitous at different stages 
of embryonic development, from as early as E7.5 to E12.512. It is obvious that Dot1L 
plays its role in various aspects of development. Even if my second hypothesis about 
calcium influx regulation by Dot1L shows promise, we need to keep our mind open to 
other possibilities. For instance, one important EPO signaling pathway is mediated by 
JAK2 and STAT5. One of the crucial target genes of STAT5 is the anti-apoptotic 
molecule Bcl-XL
6. In my studies, I observed more progenitor cells undergoing apoptosis 
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during erythropoiesis when Dot1L is deficient. A likely explanation, as I discuss 
previously, is due to abnormally high levels of intracellular calcium in Dot1L KO 
progenitor cells. Another possibility would be dysregulation of factors in the apoptotic 
pathway, such as Bcl-XL. In the future, it would be helpful if we can analyze and compare 
the expression and regulation of critical apoptotic factors between Dot1L KO progenitors 
and wild type cells during erythropoiesis.  In addition, I observed cell cycle defect in 
Dot1L KO progenitor cells during erythropoiesis. Our results and others also point out 
that the cell cycle effect of Dot1L might be tissue- and cell type-specific7,92,108. It would 
be interesting to perform cell cycle analysis in the erythropoietic lineage and other cell 
types in Dot1L KO embryos. If the defect is specific and limited to erythropoietic cells, 
this would be another possible mechanism for the erythropoietic defect. 
            5.4 Conclusion remarks 
            In this dissertation, I demonstrated the role of DOT1L methyltransferase in 
embryonic development and erythropoiesis, and in the regulation of critical genes in 
hematopoiesis. The morphological, cell cycle, and apoptotic defects in erythropoiesis 
suggest Dot1L KO progenitors fail to respond to lineage specific growth factor(s). This 
has been supported by my hypothesis indicating that EPO signaling pathway is interfered 
with in Dot1L KO progenitors. Future work using powerful in vitro models, such as iPS 
cells, will provide more consolidated support for my hypothesis and further elucidate the 
pathway. Exploration of other possible mechanisms will give us a more comprehensive 
understanding of DOT1L’s role in hematopoiesis, which will not only provide insight 
into the complex regulatory network of normal hematopoiesis, but also shed light on the 
potential therapeutic aspects of a variety of clinical diseases. 
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